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1. INTRODUCTION 
 
The initial description of genomes organization has consisted in the separation 
between regulatory and protein-coding DNA stretches. 
This simple and elegant model has supported the “one region-one function” theory: a 
genome is a linear arrangement of functional elements interspersed with non-
functional regions. 
Recently the advances in transcriptomics technologies have shown that a genomic 
region can be used for different purposes and that functional elements can co-locate in 
the same region of the genome. 
In-depth analysis of the transcriptional output of human-mouse and fly genome has 
revealed that the information content of the genome is growing exponentially along 
with the organism complexity (Taft et al. 2007). 
Estimates made by the Encyclopedia of DNA elements (ENCODE) predicts that as 
much as 93% of the genomic sequences seems capable of being transcribed (Birney et 
al. 2007). 
Pervasive transcription of the genome is mainly due to long non-coding RNAs 
(ncRNAs) and transcribed repetitive sequences, such as SINEs (short interspersed 
nuclear elements) and LINEs (long interspersed nuclear elements).  
1.1 Non-coding RNAs 
 
In the recent version of the genome annotation (Ensembl 60 release) the coding 
regions of the human genome are estimated to occupy ∼ 34 Mb, which means 1.2% of 
the euchromatic genome. Furthermore, both cDNA libraries and genome tiling array 
studies proved that the portion of the expressed transcripts is underestimated (Bertone 
et al. 2004; Carninci et al. 2005; Cheng et al. 2005; Jongeneel et al. 2005; Kapranov 
et al. 2005).  Large scale cDNA analysis of the mouse genome revealed that in front 
of 22287 protein coding transcripts, additional 34000 do not appear to encode for 
proteins.  
By an integrated analysis of genome tiling arrays (Cheng et al. 2005) and massively 
parallel signature sequencing (MPPS) data (Jongeneel et al. 2005) many thousands of 
non-coding transcripts have been located to intronic sequences and over 37% of 
MPPS signatures have matched known loci outside of annotated exons, interestingly, 
20% of them reside in the complementary strand of known transcripts. These data 
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suggest the transcription of at least 50000 different RNAs that have not been 
previously annotated in the human genome.  
A large portion of these transcripts belongs to two RNA fractions that have not been 
previously characterized in details: poly A- RNAs and the nuclear-restricted poly A+ 
RNAs (Kiyosawa et al. 2005).  
Until recently, most of the known non-coding RNAs fulfilled the relative generic 
function of being ‘infrastructural’ RNAs, such as rRNAs and tRNAs (involved in 
translation), spliceosomal uRNAs and small nuclear RNAs (snRNAs) (involved in 
splicing) and small nucleolar RNAs (snoRNAs) (involved in the modification of 
rRNAs).  
Besides their structural role, some of these ncRNAs partecipates in regulatory 
processes. For examples, U1 RNA is an interactor of TFIIH and regulates RNA 
transcription (Kwek et al. 2002); small RNAs with similarity to box H/ACA sno RNA 
are components of telomerase and mutated in a genetic form of dyskeratosis 
congenital (Vulliamy et al. 2001); 7SL RNA is a component of the Signal 
Recognition Particle  (SRP) that plays a key role in the delivery to the ER for proteins 
with a leader sequence (Nagai et al. 2003).  
 
The world of ncRNA adds new members on almost a daily basis. Several types of 
classification have been proposed based on the length of the RNA species, their 
locations on the genome and their function. 
Here I will divide ncRNAs in small and long RNAs and I will provide representative 
examples for each class. 
1.1.1 Small nucleolar RNAs  
 
Sno-RNAs generally range from 60 to 300 nucleotides and guide the site-spcific 
modification of nucleotides in target RNAs via short region of base-pairing. There are 
two classes of snoRNAs: the box C/D snoRNAs that guide the O’-ribose-methylation, 
and  the H/ACA box which drives the pseudouridylation of target RNA. Initially it 
was thought that snoRNAs functions were restricted to rRNA modification in 
ribosome biogenesis, given their specific nucleolar locazation. Now it is evident that 
that they can target other cellular RNAs, as evidenced by the snoRNA involved in the 
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aberrant splicing of the serotonin receptor 5-HT-(2C)R gene in Prader-Willi 
syndrome patients (Kishore and Stamm 2006).  
Although the snoRNA involved in ribosome biogenesis are located in the nucleolus, a 
subset of C/D snoRNAs is located into Cajal bodies (Meier 2005). Most of them come 
from intronic regions of protein-coding genes, but apparently some snoRNAs are 
independently transcribed as evidenced by the presence of methylated guanosine at 
their 5’ end (Kiss 2002). 
1.1.2 MicroRNAs and small interfering RNAs 
 
miRNA and siRNA are 22 bps nucleotides long RNAs that derives from stem-loop or 
double-stranded RNA precursors. These miRNAs are transcribed by RNA polymerase 
II from introns of numerous protein-coding and non-coding genes (Lee et al. 2004; 
Rodriguez et al. 2004) as primary miRNA (pri-miRNA) transcripts. The hairpin 
structure formed in these primary miRNA transcripts are processed by RNAse-III 
enzyme Drosha into pre-miRNA and finally into mature miRNA by Dicer. 
The mature miRNA is then incorporated into RISC complex and guides the RISC to 
the 3’ UTR of target mRNA which results into either cleavage, or translational 
inhibition of the target mRNA (Bartel 2004). It is thought that the nature of base 
pairing determines whether the target RNA will be degraded or translation will be 
inhibited (Bartel 2004). 
 miRNA suppress translation via non-perfect base-pairing at the 3’ UTR of target 
mRNAs or cause degradation of target RNA via activation of the RISC 
endonucleolitic complex in case of perfect complementarity whit the target site (RNA 
interference). miRNA derived from introns or exons of numerous protein-coding and 
non-coding genes (Lee et al. 2004; Rodriguez et al. 2004) as well as from 
retrotransposon sequences (Smalheiser and Torvik 2005). The expression of miRNA 
is a process tightly regulated and has been estimated central in several processes 
including cell proliferation (Brennecke et al. 2003), left-right patterning, neuronal 
gene expression (Klein et al. 2005), cell-fate, brain morphogenesis (Giraldez et al. 
2005), muscle differentiation (Naguibneva et al. 2006) and stem-cell division (Croce 
and Calin 2005). miRNA have also a unequivocal role in human diseases, for example 
sequence variants in the binding site for miR-189 in the SLITRK1 mRNA have been 
linked to Tourette’s syndrome (Abelson et al. 2005). miRNA expression is clearly 
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disregulated in cancer cells (Iorio et al. 2005). As an other example of involvement in 
cancer, the proto-oncogene c-myc drives the expression of a cluster of six miRNAs on 
human chromosome 13; this cluster contains two miRNA (miR17-5p and miR-20a) 
that act as translational downregulator of the E2F1 factor that is a cell-cycle 
progressor (O'Donnell et al. 2005). Dysregulation of miR17-5p and miR-20a is 
observed in various cancer cell models.  
Interestingly, miRNA were thought to interfere with translation of target mRNAs by 
incomplete base pairing at the 3’UTR. However, in 2004 two groups described that 
HOX gene suppression is dependent on a perfect match between the target mRNA 
and the miRNA which was causing post-transcriptional gene silencing via RNAi 
mechanism (Yekta et al. 2004).  
Recent studies have shown that miRNA do not require evolutionary conservation and 
many newly discovered human RNA seem to be primate specific and drive ‘higher’-
mammals’ specific fine tuning in gene regulation (Bentwich et al. 2005).  
1.1.3 Piwi-interacting RNA (piRNA) 
 
Piwi interacting RNAs were first identified from mouse testis as component of MILI 
ribonucleoprotein complex (Aravin et al. 2006). These RNAs are 24-30 nucleotides 
long and are generated by a Dicer independent mechanism. The mature piRNAs have 
5’ uridine monophosphate and a 2 -O-methylated 3’ end (Aravin et al. 2006). Piwi 
family proteins are a subclass of argonaute proteins found in all multicellular 
organisms with a highly conserve expression pattern in the germ cells which indicates 
their importance in germ cell development (Aravin et al. 2007a). 
Mutation in the Piwi proteins in Drosophila results in the activation of transposons 
and retrotransposons and loss of germline stem cells in both males and females (Cox 
et al. 1998). The Drosophila Piwi-associated small RNA are derived mostly from the 
repeat regions and retrotransposons and are therefore called repeat associated siRNA 
(rasiRNA) (Brennecke et al. 2007). However, in the case of mouse only a small subset 
of piRNA are derived from repeat regions and retrotransposons (Aravin et al. 2006). 
Interestingly, mutation of the Piwi homolog MIWI, MIWI2 and MILI leads to the 
degeneration of male germline (Aravin et al. 2007b). 
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1.1.4 Promoter-associated small RNAs (PASRs) 
 
Promoter-associated small RNAs (PASRs) are broadly defined as short transcripts 
within a few hundreds bases of the transcription start site (TSS) of protein-coding and 
noncoding RNAs. They have been described in all major eukaryotic lineages. An 
hidden repertoire of TSS-proximal transcripts first emerged from gene expression 
studies after removal of specific exosome components in plants and human cells 
(Chekanova et al. 2007; Preker et al. 2008). Small RNAs of at least 70 nts long co-
linear with the 5’ end of  mRNAs have been then described in almost all genes in 
physiological conditions (Guenther et al. 2007). 
At least three classes of these RNAs have been identified to date: 1) Promoter-
associated small RNAs (PASRs) are generally 20–200 nt long, capped, with 5' ends 
that coincide with the TSSs  (Fejes-Toth 2009; Kapranov et al. 2007a). They have 
been first detected using genome-wide tiling arrays of human cell lines and 
subsequently analyzed with high-throughput sequencing. Their biogenesis is not well 
understood, although it may result from transcription of independent, capped, short 
transcripts or from cleavage of larger capped (m)RNAs (Fejes-Toth 2009); 2) 
Transcription start site associated RNAs (TSSa-RNAs) are 20–90 nt long and 
localized within -250 to+50 of TSSs (Seila et al. 2008); 3) transcription initiation 
RNA (tiRNA) are predominantly 18 nt in length and found in human, mouse, chicken 
and Drosophila. Their highest density occurs just downstream of TSSs with positional 
conservation across species (Kapranov et al. 2007a; Taft et al. 2009).  
All three classes are strongly associated with highly expressed genes and with regions 
of RNA Pol II binding. They are weakly expressed, showing a bidirectional 
distribution that mirrors RNA Pol II  (Fejes-Toth 2009).  
Interestingly, several studies have indicated that short 19-21 nts RNAs directed to 
promoter regions can be regulators of gene expression. In some cases gene silencing 
has been induced (Morris et al. 2004), whereas in others examples gene activation 
was surprisingly triggered (Janowski et al. 2007). Interestingly, analysis of PASRs-
mimetics (20-250 nts) directed in trans against MYC and CTGF genes indicates that 
their levels correlate with decreased expression of the corresponding mRNAs (Fejes-
Toth 2009).  
The manipulation of PASRs may thus be gene-specific and leading to positive or  
negative regulation of target gene expression (Janowski et al. 2007).  
 12 
1.1.5 Long non-coding RNAs (lncRNAs) 
 
LncRNAs are arbitrarily considered as ncRNAs whose length range from 200 nt to 
several kilobases and include all those long ncRNAs implicated in dosage 
compensation and imprinting, i.e Xist and HOTAIT (Brown et al. 1992; Rinn et al. 
2007).  
These mRNAs can be grouped into a remarkably diverse set of transcripts. One 
classification has been based on their ability to be “cis-acting” or “trans-acting” 
lncRNAs. 
The estimated number of long lncRNAs is 17,000 in the human and 10,000 in the 
mouse genome. The number is likely to be greatly underestimated since many 
primary transcripts are often processed into smaller ncRNAs.  
In contrast to most mRNAs, which ultimately localize to the cytoplasm after 
processing, most long ncRNAs are localized in the nucleus at steady state. This is 
especially true for poly A- long ncRNAs that account for a large portion of the total 
transcribed sequences (Wu et al. 2008) and lncRNAs transcribed from intronic 
regions (Cheng et al. 2005).  Just a small subset of lncRNAs is located in both the 
nucleus and the cytoplasm (Cheng et al. 2005; Imamura et al. 2004; Kapranov et al. 
2007b; Wu et al. 2008) while some lncRNAs seem to be selectively localized in the 
cytoplasm (Louro et al. 2009). 
A critical role of lncRNAs has been assessed in epigenetic regulation by driving 
chromatin-modifying factors/complexes to specific locations in the genome and in 
subnuclear sites (Chen et al. 2008b; Khalil et al. 2009; Rinn et al. 2007; Sanchez-
Elsner et al. 2006; Zhao et al. 2008). 
Recently, a genome-wide ChIP-RNA sequencing analysis found that up to 38% of the 
3300 conserved large intergenic ncRNAs are associated with one of the following 
four chromatin-modifying factors: EZH2, SUZ12, CoREST, and JARID1C/SMCX 
(Khalil et al. 2009). LncRNAs may form RNA:RNA or RNA:DNA structures, which 
provide sequence specificity and serve as platforms to bind proteins that are not 
strictly sequence-specific, and to orient them to target sites (Mattick and Gagen 
2001). 
Tiling arrays covering all four human HOX clusters identified 231 novel ncRNAs, 
which are spatially expressed along developmental axes and show distinct histone 
methylation patterns (Rinn et al. 2007). Among these, a 2.2 kb lncRNA, HOTAIR, 
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transcribed from the boundary of two diametric chromatin domains in the HOXC 
locus was preferentially expressed in posterior and distal sites. HOTAIR recruits 
Polycomb repressive complex 2 (PRC2) complex in trans across 40kb of the HOXD 
locus on chromosome 2, it promotes histone H3K27 trimethylation leading to 
transcriptional repression of HOXD locus. 
Despite the fact that most of the reported ncRNA-associated chromatin-modifying 
complexes are involved in gene repression, an equally large numbers of lncRNAs can 
recruit co-activator complexes, including components of the 
trithorax/COMPASS/MLL complex (Beisel et al. 2007; Schoeftner et al. 2006; 
Schuettengruber et al. 2007). As an example, a lncRNA Evf2 serves as a transcription 
coactivator in the developing mouse forebrain. Evf2 is a long, polyadenylated ncRNA 
transcribed from an ultraconserved intergenic enhancer region and its expression 
correlates with increased transcription of the Dlx-5/6 locus (Feng et al. 2006).  
It is also possible that ncRNAs can alter their structure on “ligand” binding and 
function as “riboswitches” (St Laurent and Wahlestedt 2007; Wickiser et al. 2005). In 
this context, promoter-associated ncRNAs can function as ligands to mediate histone 
modifications as exemplified by the case of CCND1ncRNAs. The CCND1ncRNAs 
are upregulated in response to genotoxic stress, CCND1ncRNAs are capable to recruit 
TLS, a member of the TET RNA-binding protein family. In turn TLS proteins binds 
to two well-known histone acetyl transferases (HAT) CBP and p300 and cause a 
substrate-specific inhibition of its HAT enzymatic activity. In this way 
CCND1ncRNAs serve to establish the hypo-acetylation status of the chromatin and 
the consequent repression of the CCND1 mRNAexpression (Wang et al. 2008).  
Analogous to the role of rRNAs in ribosome assembly, lncRNAs can exert functional 
roles in specific nuclear organelle assembly, exemplified by the actions of the 
lncRNA NEAT1 (MEN ε/β), which is functionally essential for structural integrity of 
nuclear paraspeckles (Sunwoo et al. 2009). Paraspeckles are subnuclear organels 
whose functions have been suggested in transcription, pre-mRNA splicing and 
nuclear retention of RNA (Fox et al. 2005). 
LncRNAs also have been shown to modulate the activity of proteins by regulating 
their subcellular localization. As an example, the transcription factor NFAT (nuclear 
factor of activated T cells) localizes to the cytoplasm. When calcium-dependent 
signals occurs, NFAT is imported into the nucleus, where it activates transcription of 
target genes (Hogan et al. 2003). One of the key regulators of NFAT trafficking is a 
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lncRNA known as NRON (noncoding repressor of NFAT) that is alternatively spliced 
(0.8–3.7 kb) (Willingham et al. 2005). By binding to members of the nucleo-
cytoplasmic trafficking machinery, NRON specifically inhibits the nuclear 
accumulation of NFAT, but not that of other transcription factors such as p53 and 
NFkB that also translocate from the cytoplasm to nucleus. 
Recent genome-wide studies suggest that the function of a significant fraction of long 
unannotated transcripts may be to serve as precursors for small RNAs <200 
nucleotides (nt) in length (Fejes-Toth 2009; Kapranov et al. 2007b). It has been 
proposed that many Promoter-Associated long ncRNAs (PALRs) may be post-
transcriptionally processed to yield many promoter-associated small RNAs (PASRs) 
(Fejes-Toth 2009). Transfection of RNA mimetics to PASRs were found to reduce 
expression of the overlapping mRNA promoter, indicating that these newly identified 
small RNAs impact gene expression (Fejes-Toth 2009). 
It is thus becoming clear that lncRNAs can have numerous molecular functions, 
including modulating transcriptional patterns, regulating protein activities, serving 
structural or organizational roles, altering RNA processing events, and serving as 
precursors to small RNAs. But it will be likely possible that newly discovered 
lncRNAs may serve to other functional paradigms. 
A major current issue is to understand how the molecular functions of these lncRNAs 
affect the organism. It is already known that lncRNAs are implicated in numerous 
developmental events (Amaral and Mattick 2008), such as the formation of 
photoreceptors in the developing retina (Young et al. 2005) and the regulation of cell 
survival and cell cycle progression during mammary gland development (Ginger et al. 
2006). The generation of specific knockout animal models will be a key tool to shed 
light on this issue and will likely definitively show hat many lncRNAs are not 
transcriptional ‘‘noise,’’ but are instead required for normal development. 
LncRNAs are also misregulated in various human diseases, especially cancer 
(Prasanth and Spector 2007), and even thought the mechanisms by which these 
transcripts affect tumor initiation and/or progression are currently unknown, some are 
already used as specific markers of tumors (de Kok et al. 2002). Considering all these 
information it is reasonable that lncRNAs can also allow us to identify new 
therapeutic pathways and may be themselves therapeutic targets of molecular 
medicine. 
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1.2 Antisense transcription 
 
Given the extend of the transcriptional overlap in the same genomic region, a large 
portion of the non-coding transcripts can be located in antisense direction to protein-
coding loci. 
It is estimated that 5880 human transcription clusters (22% of those analyzed) form 
sense–antisense pairs with most antisense transcripts being ncRNA (Chen et al. 2004), 
an arrangement that exhibits considerable evolutionary conservation between the 
human and pufferfish genomes (Dahary et al. 2005). A detailed analysis of the mouse 
transcriptome indicated that 43553 transcriptional units (72%) overlap with transcripts 
coming from opposite strand (Dahary et al. 2005).. 
A large fraction of Natural Antisense Transcripts (NATs) are expressed in specific 
regions of the brain, supporting the idea that they’re involved in sophisticated 
regulatory brain functions and may be involved in complex neurological diseases 
(Qureshi et al. 2010). 
NATs appear to be involved in different cellular pathways, although it remains 
unclear whether they present any special sequence or structure-related feature as well 
as what are their protein partners. 
As far as we know, NATs appear to be an heterogeneous group of regulatory RNAs 
with a variety of different biological roles and specific pattern of expression (tissues, 
cells, developmental stages). 
1.2.1 Classification based on cis vs. trans NATs. 
 
Many well-characterized regulatory ncRNAs acts in cis as receivers of other trans 
acting signals by forming secondary structures. Several examples of cis –acting RNAs 
are provided by the regulatory sequences found in the UTRs of mammalian genes that 
are known to be target of different processes: RNA editing, control of mRNA stability 
and/or translatability (Gebauer and Hentze 2004; Kuersten and Goodwin 2003; Moore 
2005). Examples for trans –acting RNAs are the so-called riboswitches that are RNA 
molecules sensitive to several metabolic pathway, capable to bind to vitamins, lipids 
or small ligands and change their allosteric conformation in consequence of binding 
(Kubodera et al. 2003; Sudarsan et al. 2003). 
Most NATs are cis-encoded antisense RNA (Kumar and Carmichael 1998; Vanhee-
Brossollet and Vaquero 1998). By definition, cis-NATs are complementary RNA with 
 16 
an overlapping transcriptional unit (TU) at the same chromosomal locus. Trans-NATs 
are complementary RNA transcribed from different chromosomal locations (Li et al. 
2008b; Makalowska et al. 2005; Sioud and Rosok 2004).  
1.2.1.1 Characteristics of Trans-NATs  
 
A recent study on Trans-NAT showed that the abundance of these regulatory 
elements is much more than previously expected.  Although the authors had applied 
very stringent criteria for selecting trans-NATs, eliminating all the NATs originating 
from repeat regions and pseudogenes, they reported that at least 4.13% of 
transcriptional units of various species are trans-NATs (Li et al. 2008b).  Particularly, 
trans-NATs represented nearly 3,000 human TUs (or 2.89% of all human TUs) (Li et 
al. 2008a).  
Trans-NATs often originate from pseudogenes or repeat regions. Repetitive 
sequences in genome and pseudogenes have long been considered to be non-
functional artifacts of transposition pathways. However, an increasing number of 
reports point to the functional role for repetitive elements in post-transcriptional 
events (Peaston et al. 2004).  Anti-sense transcription of pseudogenes may constitute 
a mechanism for controlling their cognate (parental) genes.   
Such a regulatory role has been demonstrated for topoisomerase I, neural nitric oxide  
synthase, inducible nitric oxide synthase (NOS2A/anti-NOS2A) and fibroblast growth  
factor receptor-3 pseudogenes (Korneev et al. 2008; Korneev et al. 1999; Weil et al. 
1997; Zhou et al. 1992).  Importantly, recent reports proposed a role for a subset of 
mammalian pseudogenes in the production of endogenous siRNAs (endo-siRNA) 
through formation of double stranded RNA (Kawaji et al. 2008; Lavorgna et al. 2004; 
Tam et al. 2008; Watanabe et al. 2008).  
1.2.1.1.1 Chimeric Trans-NATs   
 
Chimeric NATs are RNAs with identity to more than one region of the genome 
(Lavorgna et al. 2004; Nigumann et al. 2002).  They offer partial complementarity to 
more than one target transcript (Li et al. 2000), being capable of regulating many 
sense mRNA at the same time.  
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1.2.2 Characteristics of Cys-NATs 
 
Cis-Antisense RNAs are widely distributed across the genome, althought they have a 
propensity for being located 5’ and 3’ to protein coding RNAs (Core et al. 2008). 
Expression of the antisense transcript is not always linked to the expression of the 
sense protein-coding partner, thus suggesting the usage of alternative regulatory 
elements. 
Antisense RNAs tend to undergo less splicing events and are often lower abundant 
than sense protein-coding partner. Knocking down antisense genes results in multiple 
outcomes, with the corresponding sense gene being either increased or decreased. 
These results indicate that antisense transcription can operate through a variety of 
different mechanisms and are a heterogeneous group of regulatory RNAs. 
Different models have been proposed for antisense –mediated regulation of sense 
gene. 
1.2.2.1 NATs regulation of transcription 
 
The act of transcription itself in the antisense direction modulates the transcription of 
the sense RNA, either for transcriptional collision or genomic rearrangements.  
The first model is based on the assumption that RNA polymerase binds to the 
promoter of convergent genes on opposite strands and collide in the overlapping 
regions, blocking further transcription (Figure 1a). 
Genomic rearrangements occurs in lymphocyte B through a recombination process in 
the variable region of immunoglobuline genes (somatic hypermutation) and in 
lymphocite T for T cell-receptor selection (class-switch recombination). 
RNA transcription from antisense direction creates a transcriptional bulge of 17 ± 1 
melted bases in the target DNA, making it accessible to the activation-induced 
cytidine deaminase enzyme (AID). This  is involved in somatic recombination and 
requires at least 5 nucleotides in ssDNA for optimal cytosine deamination (Figure 
1b). 
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Figure 1: Transcription-related modulation a) Collision: In this model RNA transcription occurring 
in anti-sense direction halts sense transcription. In this model transcription occurs in only one direction 
at a given time. b) Genomic rearrangements: In B and T limphocytes natural antisense transcription 
opens a transcriptional bubble that exposes ssDNA to the activation-induced cytidine deaminase, 
conversion of deoxycytidine in deoxyuridine, a process that underlies somatic hypermutation 
 
1.2.2.2 NATs-DNA interactions 
 
NATs may also be involved in epigenetic regulation of transcription thought DNA 
methylation, chromatin modification and monoallelic expression. 
Antisense RNA molecule itself can bind to complementary DNA target locus and  
triggers DNA methylation, DNA demethylation and chromatin modification of non-
imprinted autosomal loci. 
Some examples of antisense-mediated transcriptional silencing occurs at promoter 
regions of a-globin gene 2 (HBA2) site, p15, p21 and progesteron receptor (PR) by 
mean of methylation and heterochromatin formation (figure 2a). The proposed 
mechanism can explain functionality even when abundance of antisense RNA 
molecules is very low. 
Pervasive antisense RNA transcription at promoter and termination region gives rise 
to promoter-associated small RNAs (PASRs) and termini associated RNAs (TASRs) 
or promoter-upstream transcripts (PROMPTs). 
The local accumulation of those small RNAs along transcribed regions overlap with 
active chromatin domain marks such as trimethylation of Lys4 of histone3 
(H3K4me3) (Figurec2b). 
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Figure 2 The RNA-DNA interaction model: a) DNA methylation The newly formed antisense RNA 
along with the template DNA can induce directly of indirectly the with DNA methyl tranferase (DMT), 
thus causing a repression of the sense RNA transcription. b) Chromatin modification Activation of 
the antisense RNA transcription results in a de-repression of the sense RNA, in particular prominent 
when the antisense RNA is located in or around the transcriptional start site (TSS) of the sense gene. 
Argonaute2 (AGO2) is thought to be involved in this process. 
 
Additionally some of the antisense-mediated epigenetic changes might spread to 
neighboring region not complementary to the antisense transcript causing either 
random monoallelic exclusion or including a whole cluster of genes such as in 
genomic imprinting of the Kcnq1 locus. Finally, the expansion process occasionally 
involves the whole chromosome such as in the X-chromosome inactivation in 
females. 
1.2.2.3 NATs and Nuclear RNA duplex formation 
 
An alternative type of antisense-mediated gene regulation is based on the formation of 
hybrid RNA duplex in the nucleus that can be target of editing enzymes. 
Alternative splicing and termination Antisense RNA can bind the sense mRNA, 
tuning the balance between different splicing forms, as it happens in the case of the 
thyroid hormone α-gene isoform variants TRα 1 and TRα 2. In a similar manner it 
can potentially cause alternative termination and polyadenylation of sense RNA 
(Figure 3Ab). 
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Figure 3. The sense RNA-antisense RNA pairing: Aa) Nuclear RNA pairing can occur locally after 
transcription interfering with Ab) RNA splicing Natural antisense transcript can cover acceptor or 
donor splice sites in the sense pre-mRNA transcript influencing the balance between different splicing 
forms. Ac) RNA editing Nuclear RNA duplex formation can recruit ADAR (Adenosine deaminase 
enzymes that act on RNA enzymes is thought to be involved in this process. 
 
Transport, nuclear retention and editing: Duplex formation between sense and 
antisense RNAs can modulate nuclear export. Nuclear retention is commonly 
observed for non-coding RNAs. Several cell stressors can mobilizing antisense RNA 
molecules thus contributing to the nuclear shuffling of the protein-coding partner 
(Figure 3Ac). 
In Drosophila melanogaster antisense transcription is also been related to RNA 
editing. Duplex RNA formation in the nucleus can recruit ADAR enzymes (adenosine 
deaminase that act on the RNA), which deaminates the target adenosine in inosine. 
1.2.2.4 NATs and cytoplasmic RNA duplex formation 
 
Cytoplasmic RNA hairpins can affect both RNA stability/ translation or cover 
miRNA binding sites on the sense mRNA. 
RNA stability alteration: the expression of the sense and antisense pair in the same 
cell can result in the activation of the endogenous siRNA processing machinery, 
which mediates sequence-specific knock-down of targeted genes. However, co-
expression of NATs with their sense counterparts, together with the frequently 
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observed concordant regulation of sense and antisense RNAs in many tissues and cell 
lines, provides evidences against endogenous siRNA being the sole mechanism of 
antisense-mediated gene regulation. 
The overlapping RNA region might affect RNA stability by reducing mRNA decay, 
protecting the 5’ of the sense RNA from exonucleolitic degradation by various 
RNAses. Antisense transcript for inducible NOS synthase (INOS) interacts with the 
AU-rich element (ARE)  binding antigen R  (HuR) suppressing iNOS degradation. On 
the contrary, antisense RNA of hypoxia inducible factor 1-α (HIF-1-α) exposes the 
ARE element in the HIF-a mRNA and reduces its stability. In the case of b-amyloid 
precursor protein cleaving enzyme (BACE), the expression of its antisense RNAs 
enhances the BACE mRNA half –life by increasing its stability. 
Translational inhibition: in the case of PU.1 mRNA, its non-coding counterpart is a 
polyadenilated RNA with longer half-life than the protein-coding RNA. NATs/sense 
RNAs binding stalls PU.1 translation between initiation and elongation steps. 
1.3 Repetitive elements  
 
1.3.1 Evolution of distinct SINEs 
 
Mammalian DNA typically contains hundreds of short interspersed elements called 
SINEs. They have been fixed in the mammalian genome since a single event of 
retrotransposition and thus have been a tremendous source of insertional mutagenesis 
through mammalian evolution. The human Alu is the most extensively studied SINE 
and it exemplifies most features of this unusual class of sequences. 
There are at least 1 billion Alus per haploid genome (Schmid 1996). Individual Alus 
share a common consensus sequence of 283 bps which is typically followed by a 3’- 
A-rich region resembling  poly(A) tail (Figure 4). 
The Alu consensus sequence is a divergent tandem dimer in which the two monomers 
are separated by a short A-rich region that flanked the ancestral monomer. Except for 
30 nt insertion in the right monomer, Alu monomers are homologous to SRP RNA, 
also known as 7SL RNA. Most Alus are flanked by short direct repeats which 
represent the duplicated insertion sites. 
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Figure 4. Alu RNA secondary structure. Secondary structure of a Pol.III transcribed Alu RNA drawn 
based on a previously determined secondary structure  and adapted to the sequence of the Alu element 
of intron 4 of the a-Fetoprotein gene . Underlined blue letters and dots indicate the binding sites of 
SRP9/14 and the tertiary base pairing between the two loops, respectively, by analogy to SRP RNA. 
 
Alu elements inherited the two highly conserved sequences A and B boxes from the 
7SL RNA promoter gene. However these elements are not sufficient to drive the 
transcription in vivo and Alus depend on flanking sequences for their expression. 
RNA Pol. III-dependent transcripts of this class are referred to as “free” Alus. Alus  
transcribed in the context of larger transcriptional units of both protein coding and 
non-coding RNAs are called “embedded” Alus. 
Non-mammals SINEs are unrelated to SRP RNA and believed to be derived from 
tRNA species. However, SINEs from mammals belong to either SRP- or tRNA-
derived superfamilies. Rodents genomes contain both SRP RNAs (B1 elements) and 
tRNA superfamily (B2) SINEs with SINEB1 basically resembling the left human Alu 
monomer. Prosimiam species have both SINEs, B1 and B2, and full-length dimeric 
Alus. This intermediate composition suggests a transition between rodents and 
human. Sequence database analysis and hybridization experiment excluded the 
presence of tRNA SINEs in human genome. The reason why Alus flourished in 
higher primate genome while tRNA SINEs are undetectable are still unknown. It can 
be either that Alus may have established a state of complete neutrality with the human 
host or more probably they have compensate their hosts with selective advantages.  
Several experimental evidences suggest that Alus may serve a variety of functions.  
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1.3.1.1 Free Alus and protein translation 
 
Schmid C. W and collegues showed for the first time that free Alus have a function, 
when reporting that they stimulate translation of co-transfected reporter genes. 
Interestingly, synthetic Alu RNPs (composed of Alu RNA in complex with SRP14/9) 
and naked Alu RNAs have opposite effect toward protein translation in cell-free 
translation system. While Alu RNA are shown to stimulate translation of reporter 
mRNA both in cells and in vivo (Rubin et al. 2002), Alu RNP acts as general inhibitor 
of protein translation (Hasler and Strub 2006a). It is known from the structure of the 
SRP Alu domain that the binding of SRP9/14 induces strong conformational changes 
in the RNA. Alu RNAs are very unstable molecules, explaining their relative low 
accumulation in normal cells (Bovia and Strub 1996) and they might be stabilized by 
SRP9/14 binding. Moreover, free Alus can bind to SRP14/9 complex in vitro (Hasler 
and Strub 2006a). Given that there are free SRP14/9 molecules, the occurrence in vivo 
of Alu RNP seems therefore very likely to take place. Expression and function of Alu 
RNAs and AluRNPs are probably tightly controlled at spacial or temporal level, 
therefore be limited to certain physiological condition, such as stress (Liu et al. 1995), 
cancer (Tang et al. 2005) or by the tissue-specific control of gene expression. Alu 
RNA and Alu RNP should therefore be considered as part of complex system in 
which the concentration of SRP14/9 molecules available to bind free Alus shift the 
balance toward Alu formation and therefore toward a general inhibition of protein 
translation.  
The exact mechanism by which Alu RNA and Alu RNP exert opposite effect on 
translation is still unraveled. Both of them seem to act at the level of translation 
initiation. The global inhibition of translation is usually exerted by controlling either 
the phosphorilation or the availability of initiation factors. In particular, under stress 
conditions, cellular protein kinase (Gebauer and Hentze 2004), when activated 
hyperhosphorilate eIF2 in its alpha subunit thus limiting the abundance of metionil 
tRNA molecules (Met-tRNAiMet) to be recruited at the cap structure. It was proposed 
that Alu-dependent control of translation involves PKR protein kinase which is 
actually known to bind in-vitro free Alus. However, it was then shown that free Alus 
stimulates translation of reporter genes in PKR knock out cells (Hasler and Strub 
2006a).  
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Intriguingly, the established effect of Alu RNAs on the translation efficiency of 
cytoplasmic RNAs is not an overall effect but specific to certain mRNAs (Hasler and 
Strub 2006b). This activity of increased translation was reported only in regard to 
newly synthesized reporter mRNAs and not for all the endogenous mRNAs of the 
cell. Since it is established that the pool of cytoplasmic mRNA comprises variegated 
mRNAs with 5′- and 3′-untranslated regions (5′- and 3′-UTRs) of different length and 
structure, the stimulatory effect might only be directed to RNA species with specific 
structures.  
Interestingly, other SINEs have been linked to translation. BC200 RNA and its 
putative murine functional analogue BC1 RNA showed protein translation inhibition 
in vitro and in vivo. BC1 RNA interferes with the formation of 48S pre-initiation 
complex via a direct interaction with eIF4A (Wang et al. 2002). Other studies have 
shown that the inhibitory effects of BC200 and BC1 RNAs were dependent on the 
poly(A) stretches of the RNA and could be competed by the addition of PABP 
(Kondrashov et al. 2005). These results suggest that the suppression is mediated 
through binding of PABP by BC1 and BC200 RNAs.  
The same studies showed that Alu RNAs also inhibited translation, albeit at lower 
extent than BC200 RNA (Kondrashov et al. 2005). These results apparently 
contradicted the stimulatory effect previously observed (Hasler and Strub 2006a) 
although the stimulation was observed at concentrations ~5- to 20-fold lower and at 
relatively short incubation times (Kondrashov et al. 2005).  
The low level of expression of repetitive elements at steady state condition might be 
the result of a selective pressure to prevent their accumulation and thereby their 
function in normal cells. The fact that Alu elements behave like cell stress genes with 
a transient overexpression during cell stress response and rapid decreases upon 
recovery (Fornace et al. 1989; Li et al. 1999) strongly suggests that these transcripts 
serve a function. Upon stress, regular cap-dependent translation of most proteins is 
greatly reduced (Patel et al. 2002) whereas the expression of a small group of proteins 
such as heat shock proteins is greatly enhanced (Rhoads and Lamphear 1995). The 
mechanisms that account for the selective translation of certain mRNAs when overall 
translation is momentaneously halted, are still incompletely understood. They may 
include the use of internal ribosome entry sites and ribosome shunting (Rubtsova et 
al. 2003).  
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The increased expression of Alu RNA under stress is consistent with a stimulatory 
role in the translation as previously proposed (Rubin et al. 2002). BC200 RNA is also 
of relatively low abundance and its presumed effect on protein translation in vivo is 
most plausibly explained by its accumulation at certain sites in neuronal cells (Tiedge 
et al. 1993). Likewise, the inhibitory effect of Alu RNPs may be spatially restricted to 
certain sites in normal cells or in cells with increased levels of Alu RNA. 
1.3.1.2 Alus and alternative splicing 
 
Altrnative splicing is the majour source for protein diversity accounting for the 30%-
60% of human mRNA that become diversely spliced. One way to acquire altertative 
splice sites is when a gene harbors mutation in its pre-existing splice donor and/or at 
the acceptor site. The final outcome is the retention of a portion of the intron itself. 
This process is called exonization (Figure 5). 
 
Figure 5. Alu RNA exonization promotes proteome diversity. Shown is an example in which 
embedded Alu RNA is exonized via alternative splicing into an mRNA. 
 
When embedded in pre-mRNAs,  Alu sequences become important mediators of gene 
expression diversity. The Alu consensus sequence contains 9 potential 5’ splicing 
sites and 14 3’ splicing sites, most of them in the minus orientation. It has been shown 
that Alus account for nearly the 6% of alternative splicing exons (Sorek et al. 2002). 
A synthetic minigene called ADAR2 containing embedded Alus in minus orientation 
alternatively at 5’ and 3’ of its pre-mRNA identified in-vivo the most favored position 
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used as splice sites (nucleotide 275 and 279 used as 3’ splicing site and 158 as 5’ 
slicing site) (Lev-Maor et al. 2003; Sorek et al. 2004). Alu RNAs embedded in 
intronic position can therefore constitute a large reservoir of protein diversity on one 
end, on the other end they can cause severe genetic disease like CCFDN (congenital 
cataracts, facial dysmorphism and neuropathy), a syndome caused by a mutation in 
intron 6 that creates an alternative spliced Alu exon (Varon et al. 2003). 
1.3.1.3 Alus and A-to-I editing 
 
RNA editing is a very well characterized post-transcriptional RNA modification. It 
consists in conversion of adenosine to inosine via the deaminase activity of a class of 
enzymes called ADARs (Adenosine Deaminase acting on RNA). 
 
 
Figure 6. Alu RNA exonization promotes proteome diversity. Alu RNA indirect repeats embedded 
in an mRNA can become double stranded and undergo A-to-I editing, resulting in Alu exonization. 
 
Alu account for the 90% of editing events in nuclear RNA (Nishikura 2006). ADAR 
enzymes preferentially edit adenosine present in double stranded RNA molecules and 
have no precise sequence specificity. Adenosine editing within an Alu sequence is 
favored when two Alus are present at a short distance in opposite orientation. This 
give rise to intramolecular base pairing events (Figure 6) as seen for NFkB1 and 
Cyclin M3 mRNAs editing (Kawahara and Nishikura 2006).  
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Furthermore, ds RNA formation has been related to nuclear retention and silencing of 
long non polyadenilated nuclear RNA (Chen et al. 2008a). 
1.3.1.4 Alu embedded in mRNA 
 
Untranslated regions (UTRs) in mature RNA have a crucial role in mRNA 
stabilization, cellular localization, export and ribosome loading. It is arguable that Alu 
insertion in 5’ or 3’ UTR portion of a mature RNA can exert a control on gene 
expression at different levels. Katerina Straub and collegues screened the human 
transcriptome to identify Alu elements contained in the transcribed UTRs of human 
cDNA library. They identified 299 Alus embedded in the 5’ UTRs of 244 transcripts 
and 2142 Alus embedded in the 3’ UTRs of 1548 transcripts 
(http://cms.unige.ch/sciences/biologie/bicel/Strub/researchAlu.html). For Alu RNAs 
embedded in 5’ UTRs of specific mRNAs, a role in inhibiting translation has been 
proved. BRCA1 presents a transcript isoform specifically expressed in cancer tissue 
that contains an Alu sequence in its 5’ UTR forming a stable secondary structure in its 
mRNA and causing a translational defect (Sobczak and Krzyzosiak 2002). Similarly, 
an antisense Alu element in the 5’ UTR of the zinc finger protein ZNF177 (Landry et 
al. 2001), in the growth hormone receptor (Goodyer et al. 2001) and in the contactin 
mRNA isoform (Rome et al. 2006) decreased the translation efficency of relative 
mRNAs. Concerning Alu elements in the 3’ UTR, it has been proposed that inverted 
Alus could generate adenine and uracile rich element called AREs, as for the LDL 
receptor transcript (Wilson et al. 1998). 
1.3.1.5 Alus and miRNAs 
 
Studing a cluster of miRNA on chromosome 19 (C19MC) which encodes 54 
miRNAs, Bochert and colleagues have shown that transcription from the internal Pol. 
III promoter of Alu element can pass throught and transcribe the downstream miRNA 
precursors before encountering a Pol. III terminator (Borchert et al. 2006; Daskalova 
et al. 2006). Moreover, an in-silico analysis has shown that about 30 miRNA exibit a 
typical short-seed complementarity with specific sequence contained within sense 
Alus embedded in the 3’ UTR of human RNA (Daskalova et al. 2006) 
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1.3.2 Mouse SINEs  
 
Cellular RNA polymerase III can transcribe SINEs due to the presence of an internal 
promoter in their 5′ region, which is composed of A and B boxes spaced 30–40 
nucleotides apart. SINE B1 family in mice originated from 7SL RNA, a component of 
SRP, involved in translation of secreted proteins in all eukaryotes. All these SINE 
families include sequences corresponding to the terminal regions of 7SL RNA with 
the central 144–182 nucleotides deleted. In contrast to human Alu, murine or rat B1 
(  140 bp) is a monomer. However, it has an internal 29-bp duplication, which 
prompted Labuda et al. to consider B1 as a quasi-dimer (Labuda et al. 1991).  
Mouse B2 RNA is encoded by short interspersed elements (SINEs), dispersed 
throughout the mouse genome, with ∼350,000 copies per cell (Kramerov and 
Vassetzky 2005). SINEB2s are transcribed by RNA polymerase III to produce B2 
RNAs that are ∼180 nucleotides (nt) in length. The promoter elements (e.g., the A 
box and B box) that drive transcription are downstream from the transcription start 
site and therefore contained within the early transcribed region of SINEB2s. The 70 nt 
at the 5′ end of B2 RNAs are evolutionary related to tRNAs, and the very 3′ end of B2 
RNAs contain an A-rich sequence conserved among all SINEs (Kramerov and 
Vassetzky 2005). 
1.3.2.1 A SINEB2 serves as a chromatin boundary element  
 
During the development of the pituitary gland, in specific cells, the murine growth 
hormone (GH) becomes transcriptionally active.  
At embryonic stage 17.5 the promoter passes from a state in which H3 is 
trimethylated at K9 site (which is a mark for condensed heterochromatin) to a state in 
which H3 is dimethylated. The chromatin boundary where this transition starts has 
been localized to a region 10–14 kb upstream of the GH transcription start site. 
Intriguingly, this region contained a SINEB2 element. 
To test the hypothesis of the boundary element, a 1.1 kb region containing the SINE 
B2 module has been tested for its enhancer blocking activity when placed between 
enhancer and the core promoter of a reporter gene and it resulted that the SINEB2 is 
necessary to block reporter gene expression. Strand specific PCR experiments showed 
that ongoing transcription through the Pol. III promoter (in sense direction) and 
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through the Pol. II (antisense direction) is important for enhancer blocking activity. 
These results suggest that a mouse SINEB2 serves as a boundary element and its bi-
directional transcription causes a developmentally relevant change in chromatin 
structure (from heterochromatin to euchromatin), which establishes a permissive 
environment that allows transcription of the GH gene (Lunyak et al. 2007) (Figure 7). 
 
 
 
Figure 7. A B2 SINE serves as a boundary element to regulate transcription during pituitary 
development in mouse cells. Bidirectional transcription of a B2SINE upstream of the growth hormone 
locus facilitates a change in chromatin structure from a repressive heterochromatic state to a permissive 
euchromatic state. 
 
Interestingly, in human cells over 9000 Alus are found within 1 kb upstream of 
transcription initiation sites, raising the possibility that some Alu SINEs might also 
affect mRNA transcription by serving as boundary elements (Dagan et al. 2004). 
tRNA genes have been found to serve as boundary elements in yeast, but the 
mechanism of function also appears to be somewhat different from that of the GH 
SINEB2 (Lunyak 2008). Although ongoing Pol III transcription of tRNA genes is 
required for boundary element function in yeast, there is no evidence of antisense Pol. 
II transcription through the tRNA genes 
1.3.2.2 SINEB2  and Alus act as trans-regulators of mRNA transcription 
 
SINEB2 and Alu RNAs may function as repressors of mRNA transcription during 
heat shock. As cells respond to heat shock, transcription of some genes is upregulated 
(e.g.,hsp70), while transcription of others is repressed (e.g., actin, and hexokinase II) 
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(Allen et al. 2004; Mariner et al. 2008). When Alu or SINEB2 RNAs are silenced , 
transcriptional repression at several genes upon heat shock is abrogated, indicating 
that SINEB2 and Alu RNAs act as inhibitor of transcription.  
 
 
 
Figure 8. SINE RNAs control the heat shock response in mouse and human cells. a, Pol. III 
transcribed SINE RNAs increase upon heat shock. b, During heat shock, mouse B2 RNA or human 
Alu RNA enters complexes at thepromoters of repressed genes. TFIIF facilitates dissociation of B1 
RNA from Pol. II. c, Heat shock activated genes are resistant to repression byB2 RNA and Alu RNA. 
 
 
In an in-vitro transcription system, Alu RNA and SINE B2 RNAs were potent 
repressors of RNA Pol. II. Interestingly, physical binding of B2 RNA and Alu RNA 
to core Pol. II has been demonstrated. Consistent with this finding, ChIP assays have 
proved that in heat shocked mouse or human cells, SINEB2 RNA or Alu RNA co-
localize with Pol. II at the promoters of transcriptionally repressed genes.  
These observations led to the model where Alu RNA and SINEB2 RNA are 
upregulated upon heat shock, bind Pol. II to enter complexes at promoters, and finally 
block transcription (Figure 8b). 
Deletion studies with SINEB2 RNA gave the first hints that these ncRNA share 
distinct functional domain. Nucleotides 81–130 of B2 RNA were fully functional for 
binding Pol. II and repressing transcription in vitro; however, further truncation to 
99–130 yielded an RNA domain capable of binding Pol. II, but lacking the ability to 
repress transcription. Similarly, deletion analysis of Alu RNA demonstrated that it 
had two separable ‘Pol. II binding’ domains and two different ‘transcriptional 
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repression’ domains (Mariner et al. 2008). 
A series of in vitro studies were performed to determine the molecular mechanism by 
which Alu RNA and B2 RNA repress transcription. Given that these ncRNAs co-
occupy promoters with Pol. II, they likely repress transcription after complexes bind 
DNA but before initiation, by preventing Pol. II from properly engaging the DNA 
after assembling into complexes with promoter-associated transcriptional factors 
(Figure 8b). B1 and B2 RNAs bind Pol. II competitively and with similarly high 
affinity, which raised the intriguing question of whether B1 RNA could block B2 
RNA from binding Pol. II and repressing transcription. This possibility was 
investigated using an in vitro transcription system, and surprisingly, B2 RNA was 
found to repress transcription when B1 RNA had been pre-bound to Pol. II (Wagner 
et al. 2010). Further experiments elucidated that TFIIF facilitates the dissociation of 
B1 RNA from Pol. II (Figure 8b). Moreover, fusing a transcriptional repression 
domain from Alu RNA onto B1 RNA created a chimeric ncRNA that remained stably 
bound to Pol. II in the presence of TFIIF, showing that repression domains make Pol. 
II–ncRNA complexes resistant to the destabilizing effects of TFIIF.  
1.3.2.3  SINEB2 and Alu RNAs act as trans-regulators of translation  
 
Cell stress dramatically increases the abundance of human full length Alu RNAs (fl 
Alu RNAs) and other mammalian SINE RNAs (Fornace and Mitchell 1986; Liu et al. 
1995). For example, heat shock causes a nearly 100-fold increase in mouse B1 RNA 
making this sparse transcript abundant (Fornace and Mitchell 1986). Mouse B2 and 
rabbit C RNAs show similar increases, indicating that the heat shock response is 
conserved by the SRP RNA and tRNA SINE superfamilies. In addition to heat shock, 
other classic cell stress treatments increase full length Alu RNAs (flAlu RNA) (Liu et 
al. 1995). Cell stress does not change the lifetime of flAlu RNA but probably 
increases Alu transcription (Liu et al. 1995). Viral infection or administering 
cycloheximide to cells also significantly increases the abundance  of SINE RNA 
(Jang et al. 1992; Jang and Latchman 1992; Panning and Smiley 1993; Panning and 
Smiley 1995; Singh et al. 1985). The induction of Alu RNA by either cycloheximide 
or heat shock occurs <20 min after subjecting cells to these stresses (Liu et al. 1995). 
The rapidity of these responses suggests that they arise from the modification of 
existing factors and do not involve either DNA demethylation or de novo synthesis. 
 32 
Do these increases in SINE RNA merely reflect an aberrant breakdown in regulation 
or are they a controlled response? Schmid has and colleagues have shown that after 
viral infection, along with a global block in protein synthesis, the cytoplasmic 
concentration of flAlu RNAs dramatically increases. The halt of translation initiation 
that we observe after exposure to viral-stress is usually due to a change in the activity 
of PKR (double-stranded RNA activated kinase). The PKR is an intracellular protein 
kinase whose function is to sense cell stresses. Upon exposure to double stranded 
viral RNA PKR increases its autophosphorylation activity and hyperphosporylate the 
alpha subunit of eiF2 complex. eIF2 is responsible for the transport of the metionil-
tRNA at the site of translation initiation. Phosphorylation of eIF2a on Ser-51 inhibits 
the formation of the ternary complex with the met-tRNA and impairs general 
translation levels. Small highly structured RNAs (like Alu RNAs) sequester PKR as 
bound monomers and inhibit its autophosphorylation, thereby potentially increasing 
protein synthesis. Since flAlu RNAs increase protein synthesis after viral infection, it 
has been proposed that.this is mediated by PKR inhibition. However, translation 
stimulation is still present in knock-out cells (Rubin et al. 2002).  
The absence of Alu RNAs in most mammals and tRNA SINEs in humans indicates 
that their sequence per se is not essential for function but their secondary structure is 
important. PKR binding primarily requires only a minimum number of base pairs 
within an RNA secondary structure so that several unrelated RNA sequences can 
functionally be Alu-substitutes as PKR inhibitors (Bhat and Thimmappaya 1983; 
Clemens 1987). As a classic example, when cells are infected and PKR activation 
blocks protein synthesis, the adenoviral VAI RNA gene inhibits virally induced PKR 
activation, restoring viral protein synthesis. Both protein synthesis and viral 
infectivity are impaired for VAI mutants. As an other example of PKR binding 
element, the gene for an entirely unrelated RNA, EBER1, rescues both infectivity and 
protein synthesis for VAI mutants (Bhat and Thimmappaya 1983).  
According to this experiment, the cell stress-induced transcripts from the tRNA SINE 
superfamily could serve the same PKR regulatory role as Alu RNA. Yet a minimal 
RNA secondary structure alone cannot be sufficient to inhibit PKR in vivo. 
Otherwise, cellular RNAs, e.g. rRNA, would present an extraordinary number of PKR 
binding sites. Presumably, rRNA and other functional RNAs are unavailable for PKR 
binding because of their subcellular location or organization into RNP structures. 
Similarly, short-lived flAlu RNA (Chu et al. 1995) could be rapidly reduced to basal 
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levels when they are no longer required for PKR inhibition. As otherwise functionless 
RNAs, the RNP structure and subcellular location of SINE RNAs could promote their 
PKR accessibility. In support of the notion that Alu RNPs are accessible for PKR 
binding, the only other proteins known to form Alu RNPs are two small SRP 9/14 
proteins and La, which transiently binds to the 3′-ends of nascent Pol. III transcripts. 
1.4 PD 
 
It is the second most common progressive neurodegenerative disorder, affecting 1-2% 
of all individuals above the age of 65. The main pathological hallmark of PD is the 
progressive loss of neuromelanin-containing dopaminergic neurons in the Substantia 
Nigra pars compacta (SNc) of the ventral midbrain and the presence of eosinophilic 
intraneuronal inclusions, called Lewy bodies (LBs), composed of specific cytoplasmic 
proteins like alpha-synuclein, parkin, synphilin, ubiquitin, and oxidized 
neurofilaments (Goldman et al. 1983). 
The result of this cell loss is a severe dopamine depletion in the striatum, responsible 
for the motor symptoms associated with PD, especially bradykinesia, tremor at rest, 
rigidity, and loss of postural control (Bernheimer et al. 1973); (Ehringer and 
Hornykiewicz 1960). While the precise pathological mechanisms remain unclear,, the 
identification of several genes associated with rare, heritable forms of PD have 
highlighted potential pathogenic causes such as mitochondrial disfunction, oxidative 
and nitrosative stress and aberrant protein degradation. 
 
Table 1. List of PD-associated loci. 
 
About 5-10% of all cases of PD are familial. Two autosomal-dominant genes, (α-
synuclein and LRRK2) and three autosomal recessive genes (parkin, DJ-1 and 
PINK1) have been repetitively found mutated in inherited PD (Bonifati et al. 2003; 
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Kitada et al. 1998; Paisan-Ruiz et al. 2004; Polymeropoulos et al. 1997; Valente et al. 
2004; Zimprich et al. 2004).  
In brief, α-synuclein was the first gene in which a mutation was identified to cause an 
autosomal-dominant form of Parkinsonism (Polymeropoulos et al. 1997). 
Furthermore, it was found to be the principal constituent of Lewy bodies (Spillantini 
et al. 1997). Its function is currently not known although it seems to be involved in 
fatty acid metabolism and synaptic transmission (Sharon et al. 2003).  
LRRK2, whose function is also unknown, is a complex kinase for which it has been 
proposed that a simple gain of function could lead to toxicity (Greggio et al. 2006).  
Parkin is an E3 ligase, whose functions in the cell may include targeting proteins for 
proteosomal degradation.  
DJ-1 is an atypical peroxidase that protects from oxidative stress.  
PINK 1 is a mitochondrial kinase. 
1.4.1 Ubiquitin Carboxy Terminal Hydrolase-1 (PARK5) 
 
Uchl1 is an abundant neuronal enzyme (1-5% of total brain protein) (Wilkinson et al. 
1989). It possesses a well characterized de-ubiquitinating activity that catalyzes the 
hydrolysis of carboxyl-terminal esters and amides of Ubiquitin to generate free 
monomeric Ubiquitin (Larsen et al. 1996). Furthemore, Uchl1 associates with 
monoubiquitin and elevates the half-life of monoubiquitin in neurons, probably by 
preventing its degradation in lysosomes. 
Interestingly, a natural Uchl1 null mutant is the Gad mouse (Gracile axonaly 
dystrophy), a mouse model of a recessively transmitted neurodegenerative disease 
characterized by progressive axonal degeneration. Loss of functional Uchl1 leads to a 
decrease of free Ubiquitin and subsequent inadequate ubiquitynilation of proteins. A 
decreased Ub-dependent degradation is clearly upstream the accumulation of non-
degradated ub-proteins observed within the spheroid bodies in gad mice.  
General involvement of UCHL1 in neurodegeneration has been assessed for 
Spinocerebellar ataxia (Fernandez-Funez et al. 2000) and Hungtinton’s disease (Naze 
et al. 2002), while its role in the pathogenesis of PD is still debated. A missense 
mutation in the UCHL1 gene leading to a I93M substitution at the protein level has 
been reported in two affected siblings in a german family with an autosomal inherited 
form of PD. However, the existence of an unaffected carrier of the I93M mutation has 
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questioned the link between I93M mutation and PD. Intriguingly, UchL1I93M 
transgenic mice exhibits a clear nigrostiatal degeneration and progressive 
dopaminergic cell loss (Setsuie and Wada 2007). Moreover, UCH-L1 I93M shows 
decreased solubility and display aberrant interaction with several cellular proteins, 
including tubulin whose polimerization is severely unbalanced in presence of mutant 
I93M or carbonyl-modified UCH-L1 (an oxidized form of UCH-L1 often found in PD 
Post-mortem brains) (Kabuta et al. 2008).   
In search for additional I93M mutants, a previously unrecognized polymorphism in 
the UCHL1 gene (S18Y) was discovered and subsequently found to be linked to a 
decreased susceptibility to PD (Levecque et al. 2001). Protection of S18Y allele is 
dependent on the dosage, that is homozygotes have significantly lower risk than 
heterozygotes. The protection exerted by S18Y is not simply linked to UCH-L1 
hydrolytic activity because S18Y variant showed similar hydrolase properties as the 
wild type. This fact suggested the existence of a distinct enzymatic activity that 
confers a gain-of-toxic-function for I93M mutant and confers protective properties to 
S18Y variant. This second activity was identified in the 2002 by the group of Peter 
Lansbury in a novel dimerization-dependent ubiquitin-ligase activity. UCH-L1 was 
reported to form K63 polyubiquitin chain in vitro, using α-synuclein as a model 
substrate (Liu et al. 2002). While I93M and wt UCH-L1 increased the α−synuclein 
levels in transfected cells inhibiting its degradation, S18Y did not.  
Uchl1 ligase activity was found to be diminished for S18Y variant, which had indeed 
a dominant negative effect toward I93M mutant in-vitro, thus explaining the 
incomplete penetrance of I93M mutation. 
Kabuta et al also showed an aberrant interaction between mutant UCH-L1 I93M and 
protein involved in chaperon mediated autophagy (CMA) machinery: LAMP2A 
Hsp70 and Hsp90 (Kabuta et al. 2008).  UCH-L1 I93M was proposed to be a negative 
regulator of the CMA pathway and to have also a role in the inhibition of α-synuclein 
shunting to lysosomes. 
Recent studies have shown classical Lewy pathology in a deceased sibling of a family 
affected by the 193M UCHL1 mutation who developed, in addition to DOPA-
responsive Parkinsonism, marked cognitive deficits (Leroy et al. 1998).  
From a clinical point of view, UCH-L1 has been extensively studied in post-mortem 
brains of neurodegenerative diseases. In Alzheimer’s Diasease (AD) brains UCH-L1 
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was also commonly found in neurofibrillary tangles with decreased levels of soluble 
protein (Choi et al. 2004). Down regulation and extensive oxidative modifications 
have been observed in post-mortem brains of both AD and PD idiopathic forms 
(Butterfield et al. 2002; Castegna et al. 2002; Choi et al. 2004). Aberrant ubiquitin 
hydrolase and or ligase activity occurring after oxidative modifications and/or 
downregulation of UCHL1 might lead to dysfunction of the neuronal 
ubiquitination/de-ubiquitination machinery, thus causing synaptic deterioration and 
neuronal degeneration. Furthermore, oxidative modification can make UCH-L1 itself 
more resistant to proteolysis and promote aggregation into hallmark lesions of AD 
and PD brains (Choi et al. 2004; Lowe et al. 1990). In fact UCH-L1 has been found in 
neurofibrillary tangles and the level of soluble UCH-L1 protein was inversely 
proportional to tangle number. The association of UCH-L1 with such structures in AD 
brains together with the lower hydrolytic activity shown by oxidized forms of UCH-
L1 and the inverse correlation with tangles number raise the possibility that its role 
may be the de-ubiquitination of posphorylated tau protein and prevention of its 
aggregation in vivo. Importantly, transduction of UchL1 protein restored enzymatic 
and synaptic activity in hyppocampal slices treated with oligomeric Ab42 peptides 
and in APP/Ps1 mice model of AD (Gong et al. 2006). 
A potential link of UCH-L1 with alpha-synuclein pathology is supported by the 
observation that inhibition of UCH-L1 activity in foetal rat ventral mesencephalic 
cultures is associated with alpha-synuclein aggregates (McNaught et al. 2002). 
Increased intracellular aggregates containing ubiquitinated proteins have been found 
after UCH-L1 inhibition by prostaglandins in human SK-N-SH cells (Li et al. 2004). 
These findings suggest that reduced UCH-L1 activity impairs UPS function and 
protein degradation, thus facilitating, under appropriate conditions, the accumulation 
of abnormal protein aggregates. In line with this, reduced UCHL1 mRNA and protein 
is found in PD and in DLB, but only in brain regions in which aggregated proteins 
occur in Lewy bodies and neuritis (Barrachina et al. 2006). 
1.5 Molecular mechanism of translational control 
 
 The mammalian translational machinery is a tightly regulated system composed by 
eukaryotic initiation and elongation factors that are responsible for the recuiment of 
ribosomes to the 5’ cap structure of cytoplasmic RNAs and for the following step of 
polypeptide chain synthesis. 
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Two predominant pathways translate mammalian mRNA throught cap-dependent and 
independent mechanism. The capping of the 5’ end of mRNA by 7metil-GTP allows 
the recruitment of eIF4F complex eIF3 and 40S ribosomal subunit to the 5’ mRNA 
cap. Cap independent translation is mediated by internal RNA structure called  
internal ribosomal entry site (IRES), which recruits the ribosome independently of 
both the cap structure and the entire eIF4F complex. 
1.5.1 Cap-dependent translation 
 
The rate-limiting step of protein synthesis is translation initiation. During this process  
the small ribosome subunit 40S is loaded on the 5’ of mRNA (7metil-GTP-capped) 
and scans toward the 3’ for the start codon AUG where the complete ribosome is 
subsequently assembled to begin polypeptide formation (Figure 9).  
 
Figure 9. Regulating cap-dependent translation initiation. Hypophosphorylated 4E-binding proteins 
(4E-BPs) bind tightly to eIF4E, thereby preventing its interaction with eIF4G and thus inhibiting 
translation. Mammalian target of rapamycin complex 1 (mTORC1)-mediated phosphorylation of 4E-
BPs releases the 4E-BP from eIF4E, resulting in the recruitment of eIF4G to the 5′ cap, and thereby 
allowing translation initiation to proceed. 
 
The recruitment of small ribosomal subunit requires the assembly of the eukaryotic 
initiation factor 4F (eIF4F) complex on the 5’ cap structure of mRNA. EIF4E (cap-
recognizing protein) binds to the 5’ 7mG of mRNAs and promotes the assembly of 
eIF4A and eIF4G. The inhibitory 4E-binding protein (4E-BP1), when 
hyperphosphorylated, releases eIF4E, allowing eIF4F complex to form (Figure 9).  
4E-BP is target of a regulated signaling pathway that controls its phosphorilation 
status and thus its ability to bind to eIF4E. 
Some mRNAs contain inhibitory secondary structures at their 5’ UTRs. They may 
encode proteins that are involved in promoting cell-growth and proliferation. An 
initiation factor belonging to the family of RNA helicases eIF4A has the proper 
function to unwind the RNA as long as the initiation complex is forming on the cap of 
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mRNAs. eIF4A activity can be significantly enhanced when associated to its 
regulatory factor eIF4B, that is target of phosphorilation pathways as well as 4E-BP1.  
1.5.1.1 The mammalian target of rapamycin (mTOR)-regulated pathway 
 
Cells respond to changes in environmental conditions by altering gene expression and 
proteins are produced as a consequence of new mRNA synthesis. However, 
translation is a tightly regulated molecular step and it has a fundamental role in 
forming the proteome of a cell. 
To grow and proliferate cells must ensures that sufficient resources are available to 
drive protein production. When amino acids availability becomes limiting, protein 
production has to be down-regulated, keeping the spare energetic resources to survive. 
Mammalian cells have evolved a fine mechanism of translational control in response 
to nutrient availability, cellular energy, stress, hormones and growth factors stimuli.  
Translational control often targets translational initiation. A key pathway that 
responds to environmental cues and integrates protein synthesis rate with external 
conditions involves target of rapamycin (TOR). TOR is part of mammalian TOR 
complex 1 (mTORC1) along with raptor (regulatory associated protein of TOR (Fig) 
and LST8. mTORC1 phosphotransferase activity is elicited toward 4E-BP and 40S 
ribosomal protein S6 kinase, that are its major downstream targets. 
 
 
Figure 10. Regulating cap-dependent translation initiation.  Following 40S ribosomal protein S6 
kinase (S6K)-mediated phosphorylation, eIF4B is recruited to the translation pre-initiation complex 
and enhances the RNA helicase activity of eIF4A. This is particularly important for translating mRNAs 
that contain long and structured 5′ untranslated region sequences, because the unwinding of these RNA 
structures is required for efficient 40S ribosomal subunit scanning towards the initiation codon. GF, 
growth factor. 
 
Normal processivity of translational machine requires that highly structured 5’ UTR 
are first linearized. This is achieved by eIF4A helicase enzymatic complex. EIF4A 
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exhibits basically low activity when not stimulated by the binding of cofactor eIF4B, 
which in turn enhances eIF4A affinity to ATP. S6K phosphorilates eIF4B near its 
RNA-binding site thus promoting its association to eIF4A (Figure 10). Mutant eIF4B 
that cannot be modified by S6K is inactive in-vitro, confirming that phosphorilation is 
both sufficient and necessary for its recruitment to the translation-initiation complex. 
1.5.2 Cap-independent translation 
 
RNA genomes of picornaviruses, such as encephalomyocarditis virus (EMCV) and 
poliovirus, have properties that are incompatible with initiation by 5′ end–dependent 
scanning. In 1988, it was discovered that picorna viral mRNAs are translated by a 
mechanism, distinct from shunting, that enables ribosomes to initiate translation 
effectively on highly structured regions located within the 5' non-translated region 
(NTRs) (Pelletier et al. 1988). These regions were named IRESs.  
Picornaviral 5’ NTRs can range in length from 610 to 1500 nucleotides, are highly 
structured, and contain multiple nonconserved AUG triplets upstream of the initiation 
codon that should act as strong barriers to scanning ribosomes. Interestingly, several 
oncogenes, growth factors and proteins involved in the regulation of programmed cell 
death, cell cycle progression and stress response contain IRES elements in their 5' 
UTRs. Internal initiation escapes many control mechanisms that regulate cap-
dependent translation. Thus, a distinguishing hallmark of IRES-mediated translation 
is that it allows for enhanced or continued protein expression under conditions where 
normal, cap-dependent translation is shut-off or compromised. For instance, IRES 
elements were found to be active during irradiation (Gu et al. 2009), hypoxia (Lang et 
al. 2002), angiogenesis (Nagamachi et al. 2010), apoptosis (Spriggs et al. 2005) and 
amino acid starvation (Gilbert et al. 2007).  
The repression of global protein synthesis associated with such stresses is in part a 
consequence of phospholylation of Ser51 on the α subunit of the translation initiation 
factor eIF2A. During one of the first step of translation, eIF2A binds to GTP and the 
initiator Met-tRNAiMet to form the ternary complex which subsequently binds to the 
40S ribosomal subunit. In a second step GTP is hydrolyzed. For recurring initiation, 
the GDP must be released and eIF2A charged with fresh GTP.  
This reaction is catalyzed by eIF2B. After phosphorylation, eIF2A is turned into an 
eIF2B competitive inhibitor, leading to a global repression of protein synthesis 
 40 
(Figure 11). 
 
 
Figure 11. Recycling of EiF2 by EiF2B and regulation by Eif2A kinases. The g subunit of eIF2 
binding to GTP is essential for the ternary complex of eIF2, GTP and Met-tRNAiMet. During the course 
of translation initiation the GTP bound by eIF2 is hydrolyzed to GDP and eIF2 is released from the 
ribosome in a binary complex with GDP. As eIF2 has a much higher affinity for binding GDP than 
GTP, a guanine-nucleotide exchange factor termed eIF2B is required to recycle eIF2•GDP to 
eIF2•GTP. 
 
Paradoxically, inhibition of eIF2B by phosphorylated eIF2A leads to upregulated 
translation of mRNAs with particular motifs in their 5’ UTRs; these motifs are 
recognizable as upstream open reading frames (uORFs) and IRES (Komar and 
Hatzoglou 2005; Stoneley and Willis 2004; Tzamarias et al. 1989; Vattem and Wek 
2004). In the genome of Saccharomyces cerevisiae a single eIF2α kinase has been 
found: general control non-derepressing (GCN)2. GCN2 is activated in response to 
nutrient deprivation and in particular to amino acids starvation (Kimball 2001). 
Mammals have 4 different eIF2α kinases, the mammalian ortholog to GCN2, the 
double-standed RNA activated kinase (PKR), the heme-controlled inhibitor and the 
PKR-like endoplasmic reticulum (ER) resident kinase (PERK). Each of these kinases 
are activated upon distinct stresses: GCN2 after deprivation of essential amino acids, 
PKR after viral infection and interferon response, HRI during heme limitation and 
PERK during ER stress or unfolded protein response (UPR). 
Phosphorylation of eIF2 α is essential for both the shut-off of global translation and 
recovery from stress. For instance, when unfolded protein accumulates in the lumen 
of ER, activated PERK mediates the phosphorylation of eIF2α. PERK-mediated 
phoshorylation of eIF2α represses the synthesis of proteins targeted to the ER thereby 
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minimizing further accumulation of unfolded proteins. Lower cellular availability of 
eIF2A-GTP bound complexes increases the chance that mRNAs with internal AUG 
are translated, as for ATF4 and ATF5 (Figure 12). 
 
 
 
Figure 12. These kinases are sensors of cellular stress. These 4 shown protein kinases are activated 
following heme-deprivation (HRI), virus infection (PKR), ER stress (PERK), and amino acid 
starvation (GCN2). Subsequent phosphorylation of eIF2a on Ser-51 inhibits eIF2B and thus impairs 
general translation. 
 
Together, these observations suggest that IRES and uORF mediate the translation 
initiation of certain mRNAs representing a regulatory mechanism that helps the cell 
cope with transient stress. It is thus reasonable that each of the eIF2α kinases would 
be required for a recovery program specific to its activating stress, hence influencing 
the translation efficency of different subsets of mRNAs. Moreover, IRES activity may 
also participate in the maintenance of normal physiological processes such as 
adequate synthesis of some proteins during cell cycle progression (Fingar et al. 2004).  
1.5 Rapamycin 
 
The ability of a cell to respond to environmental stress is a fundamental property that 
allows survival. mTOR signaling is activated downstream to numerous growth stimuli 
responding mainly to the Akt/PI3K pathway. Thus, TOR signaling coordinates cell 
growth and metabolism in response to physiological changes and elicits its control 
mainly via phosphorilaton of its target 4E-BP as previously described.  
Inhibition of cap-dependent translation is essential for survival under stress 
conditions. Many cellular stressors result in the rapid cessation of overall cap-
dependent translation and promotion of cap-independent translation of several pro-
survival factors. Overexpression of the translational inhibitor 4E-BP1 or treatment 
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with mTOR inibitor rapamycin (that diminishes 4E-BP1 molecules able to exert the 
translational inhibition itself) has been shown to possess viable therapeutic potential 
for PD. 
Mutation in two genes, PARK1, which encodes for an E3 ubiquitin ligase (Parkin) 
and PARK2, which encodes for a mitochondrial targeted kinase (Park2), result in 
autosomal recessive parkinsonism. PINK1 and Parkin are component of a common 
pathway whose function is essential to maintain mitochondrial integrity (Clark et al. 
2006; Exner et al. 2007). 
In Drosophila PINK1 and parkin mutants exhibit dopaminergic neurodegeneration, 
locomotor deficits and mitochondrial dysfunction, representing a reliable animal 
model of PD. 
A genetic screening on mutants has identifyied in the Drosophila Thor a modifier 
gene capable to influence the Parkin-/- genotype. Thor encodes for the sole ortholog 
of the mammalian 4E-BP1. 4E-BP1 as described before, is a known translational 
repressor that sequester eIF4E and prevents its binding to the 5’-cap of cytoplasmic 
mRNAs.  
It has been proved that 4E-BP1 mediates the survival response of cells exposed to 
various stresses (Clemens 2001; Richter and Sonenberg 2005). A regulated control of 
translation is believed to be the strategy used by cells to elicit a rapid response to 
toxic insults aiming to immediately change protein synthesis from pre-existing 
mRNAs pools.  
Loss of 4E-BP markedly reduced the viability of double mutants for Parkin and PINK 
1. On the contrary, overexpression of 4E-BP1 was sufficient to suppress all the 
pathologic phenotype in Parkin/PINK1 double mutants, included neurodegeneration 
(Tain et al. 2009). The same protective effect in-vivo is achieved by rapamycin-driven 
pharmacological inhibition of TOR. 
Rapamycin is a macrolide antibiotic produced by Streptomyces hygroscopicus, which 
binds FKBP-12 (FK506 binding protein). Thereby, the rapamycin–FKBP12 complex 
can inhibit mTOR preventing further phosphorylation of S6K, 4E-BP1 and, indirectly, 
other proteins involved in transcription, translation and cell cycle control. 
Rapamycin has been recently found to provide neuroprotection in PD models 
(Malagelada et al. 2010). Primary neurons pre-exposed to Rapamycin are protected by 
different neurotoxins that are known to recapitulate PD pathogenesis. More 
importantly, the infusion of rapamycin in the brain of mice treated with the PD 
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mimicking drug MPTP (1-metil 4-phenil 1,2,3,6-tetrahydro-piridin) rescues neurons 
from undergoing degeneration.   
The neuroprotection is exerted at different levels: 1) Rapamycin promotes autophagy 
in neurons; protein aggregates and organelles damaged by PD-mimicking neurotoxins 
would be cleared by autophagic process; 2) Rapamycin suppresses the expression of 
pro cell death proteins known to induce neuronal apoptosis. One of these proteins is 
RTP801, a transcription factor that is induced during Parkinson’s disease and 
neuronal oxidative stress (Malagelada et al. 2006a; Ryu et al. 2002). 3) Rapamycin 
maintains the activation status of neuroprotective signaling pathways in neurons such 
as the pro-survival Akt pathway (Malagelada et al. 2008). Importantly, rapamycin 
treatment is also able to rescue mitochondrial defects in parkin-mutant PD patients-
cells. Other studies have shown that rapamycin significantly reduces the toxic build-
up of protein aggregates such as amyloid beta and huntigntin proteins in vivo and in 
vitro models of AD and HD (Sarkar and Rubinsztein 2008; Yu et al. 2005). 
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2. METHODS 
 
Plasmids 
 
Full length AS Uchl1:  Full length DNA sequence of AS Uchl1 was amplified via 
fusion PCR starting from RACE fragment and FANTOM clone Rik6430596G22 with 
the following primers: 
For mAS Uchl1 fl: 5’-ACAAAGCTCAGCCCACACGT-3’  
Rev mAS Uchl1fl: 5’-CATAGGGTTCATT -3’ 
Uchl1: Mouse Uchl1 mRNA was cloned from FANTOM 2900059O22 with the 
following primers: For mUchl1: 5’-ATGCAGCTGAAGCCGATG-3’  
Rev mUchl1: 5’-TTAAGCTGCTTTGCAGAGAGC-3’ 
AS Uchl1 shRNA: Oligo containing the sequence -14/+4 around the TSS of AS Uchl1 
CGCGCAGTGACACAGCACAAA was cloned into pSUPERIOR.Neo.GFP vector 
(OligoEngine). Scrambled sequence was also cloned and used as control.  
AS Uchl1 Δ5’: 5’ deletion mutant was generated by PCR using the following 
oligonucleotides:  
For mAS Uchl1 fl  
Rev Δ 5’AS Uchl1: 5’-TACCATTCTGTGCGGTGCA-3’ 
AS Uchl1Δ3’: 3’ deletion mutant was generated by PCR using the following primers:  
For mAS Uchl1: 5’-GACCTCCTCTAGCACTGCACA-3’ 
Rev mAS Uchl1 fl 
AS Uchl1 Δ(Alu+SINEB2): This mutant was obtained by subsequent cloning of PCR 
fragment I (NheI-EcoRI site) and PCR fragment II (EcoRI-HindII site) into 
pcDNA3.1. Primers used to amplify AS Uchl1 to generate fragments I and II were the 
following: 
PCR fragment I:  
For mAS Uchl1 fl   
Rev pre-SINE B2 5’-CAATGGATTCCATGT-3’  
PCR fragment II: 
For post-ALU 5’-GATATAAGGAGAATCTG-3’  
Rev mAS fl 
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AS Uchl1 ΔAlu: This mutant was generated with a similar strategy than AS Uchl1 
ΔAlu+SINEB2. Below are the primers to obtain PCR fragment I and II. 
PCR fragment I:  
For mAS Uchl1 fl   
Rev pre-SINE B2 5’-CAATGGATTCCATGT-3’  
PCR fragment II: 
For post-ALU 5’-GATATAAGGAGAATCTG-3’  
Rev mAS fl 
AS Uchl1 ΔSINEB2: This mutant was obtained as described before. Oligonucleotides 
used for the PCR: 
PCR fragment I: 
For mAS Uchl1 fl and  
Rev pre-SINE B2: 5’-CAA TGGATTCCATGT-3’ 
PCR fragment II: 
For post-SINE B2: 5’-GAATTCCTCCAGTCTCTTA-3’  
Rev mAS fl 
AS Uchl1 (Alu+SINEB2) flip: PCR fragment obtained with the following primers was 
cloned in the unique EcoRI site of AS Uchl1 ΔAlu+SINEB2: 
For SINE B2 inside: 5’-TGCTAGAGGAGG-3’  
Rev Alu flip: 5’-GTCAGGCAATCC -3’  
AS Uchl1 SINEB2 flip: PCR fragment obtained with following primers was cloned in 
the unique EcoRI site of AS Uchl1 ΔSINEB2: 
For SINE B2 inside: 5’-TGCTAGAGGAGG-3’  
Rev SINE flip: 5’-AAAGAGATGGC-3’ 
Cells 
 
MN9D cells were obtained from Prof Michael J. Zigmond at University of Pittsburg. 
Cells were seeded in 10 mm dishes in Dulbecco’s modified Eagle’s (DMEM) medium 
containing 10% fetal bovine serum (Invitrogen) supplemented with penicillin (50 
units/ml) and streptomycin (50 units/ml). When required, cells were treated with 
1µg/ml Rapamycin (R0395, Sigma) for 45 minutes. 
For the establishment of stable cell lines (siRNA -15/+4, siRNA scrambled, pcDNA 
3.1- and AS Uchl1ΔSINEB2), MN9D cells were seeded in 100mm petri-dishes and 
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transfected with Lipofectamine 2000 (Invitrogen) according to manufacturer’s 
instruction. Stable clones were selected by 500µM Neomycin (N1142, Sigma). HEK 
cells (SIGMA) were cultured under standard condition in Dulbecco’s modified 
Eagle’s medium containing 10% fetal bovine serum supplemented with antibiotics. 
Transient transfections were done with Lipofectamine (Invitrogen). 
MN9D-Nurr1Tet-On cells(Hermanson et al. 2003) were obtained from Dr. Perlmann 
(Ludwig Institute for Cancer Research, Stockholm, Sweden). Cells were maintained 
in DMEM/F12 medium (Invitrogen) supplemented with 10% fetal bovine serum, in 
presence of penicillin (50 units/ml), streptomycin (50 units/ml) and 250 mM 
Neomycin. Nurr1 expression in MN9D-Nurr1Tet-On cell lines was induced by addition 
of 3 µg/ml doxycycline hyclate (Sigma) to the culture medium. Cells were grown as 
above except that the 10% serum was changed to 5% Fetal Bovine Serum.  
RACE and multiplex RT-PCR 
 
The 5’ UTR of AS Uchl1 was amplified by RACE PCR (GeneRacer, Invitrogen) by 
MN9D total RNA and cloned into pGEM®-T Easy vector (Promega).  
Multiplex RT-PCR was performed with SuperScript® III One-Step RT-PCR System 
with Platinum® Taq DNA Polymerase (Invitrogen). 500 µg of total RNA was first 
DNAse-treated and then retro-transcribed in presence of reverse primers for Gapdh, 
Uchl1, AS Uchl1 for 60 minutes at 60 degrees. For PCR amplification forward 
primers were then added at final concentration of 200nM to the reaction.  
qRT-PCR 
 
Total RNA was extracted using Trizol reagent (Invitrogen) according to 
manufacturer’s instructions. Purified RNA was subjected to DNAse I treatment 
(Ambion) and 1µg was retro-transcribed using iScript cDNA Synthesis Kit (BioRad). 
Real Time qRT-PCR was carried out using Sybr green fluorescence dye (2X iQ5 
SYBR Green supermix, BioRad). Actin and Gapdh were used as internal standard. 
Relative quantification was performed with the comparative Ct method. Briefly, the 
results were normalized to β-actin and /or GAPDH. The initial amount of the template 
of each sample was determined as relative expression versus one of the samples 
chosen as reference. Relative expression in each sample was calculated by the 
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formula 2xΔΔCt (User Bulletin 2 of the ABI Prism 7700 Sequence Detection System). 
Below are the primers used:  
Gapdh F: 5’-GCAGTGGCAAAGTGGAGATT-3’ 
Gapdh R: 5’-GCAGAAGGGGCGGAGATGAT-3’ 
Beta-actin F: 5’- CACACCCGCCACCAGTTC-3’  
Beta-actin R: 5'- CCCATTCCCACCATCACACC-3’ 
AS Uchl1 F:  5’CTGGTGTGTATCTCTTATGC-3’ 
AS Uchl1 R: 5’CTCCCGAGTCTCTGTAGC-3’ 
TH qPCR F: 5’- CCGTCTCAGAGCAGGATACC-3’  
TH qPCR R: 5’- CGAATACCACAGCCTCCAATG-3’ 
AS Uchl1 overlap F: 5’-GCACCTGCAGACACAAACC-3’,  
AS Uchl1 overlap R: 5’-TCTCTCAGCTGCTGGAATCA-3’ 
Uchl1 F: 5’-CCCGCCGATAGAGCCAAG-3’ 
Uchl1 R: 5’-ATGGTTCACTGGAAAGGG-3’  
ASUchl1 pre RNA F:  5’-CCATGCACCGCACAGAATG-3’  
AS Uchl1 R: 5’-GAAAGCTCCCTCAAATAGGC-3’  
Pre_ribosomal RNA F: 5’-TGTGGTGTCCAAGTGTTCATGC-3’ 
Pre ribosomal RNA R: 5’-CGGAGCACCACATCGATCTAAG-3  
AS_Uxt F: 5’-CAACGTTGGGGATGACTTCT-3’ 
AS Uxt R: 5’-TCGATTCCCATTACCCACAT-3’  
Uxt F: 5’-TTGAGCGACTCCAGGAAACT-3’ 
Uxt  R: 5’-GAGTCCTGGTGAGGCTGTC-3’ 
Laser Capture Microdissection technology (LCM) 
 
For LCM, regions of midbrain from TH-GFP/21-31 mice were dissected and 
incubated in 1X Zincfix solution for 6 hours. They were then cryoprotected in 30% 
sucrose solution at 4˚C overnight, embedded in Neg-50 section medium, snap-frozen 
and left to equilibrate in a cryostat chamber at -21˚C for 1 hour before sectioning, as 
described earlier(Biagioli et al. 2009). Cryostat 14 µm midbrain coronal sections were 
thaw-mounted on Superfrost plus glass slides (Mezzle-Glasser) and dopaminergic 
GFP+ cells were harvested via LCM and collected in microfuge (PALM adhesive 
caps). RNA was immediately extracted using Absolutely RNA® Nanoprep Kit 
(Stratagene), eluted in RNAse /DNAse free water (Ambion) and retro-transcribed. 
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Double Fluorescent in situ hybridization (D-FISH) 
 
After perfusion with 4% formaldehyde, mouse brain was cryoprotected overnight in 
30% sucrose. In situ hybridization was performed on cryostat slices (16 µm). Sense 
and antisense probes were generated by in vitro transcription from the cDNA 
encoding the distal 600 bps of mouse Uchl1 cDNA and the last 1000 bps of mouse 
AS Uchl1. The probes for Uchl1 and AS Uchl1 were labeled with digoxigenin (DIG 
labelling, Roche) and biotin (BIO-labelling mix, Roche), respectively. Incorporation 
of biotin and digoxigenin was checked via Northern Blot. ISH was performed as 
described previously(Ishii et al. 2004). Slices were pre-treated with hydrogen 
peroxide 3% for 30 minutes. Hybridization was performed with probes at a 
concentration of 1 µg/ml (Uchl1) and 3 µg/ml (AS Uchl1) at 60°C for 16 h. For 
biotinilated RNA detection, streptavidin-HRP (Amersham Bioscience) was used 
(1:250) for 2 hours in TNB buffer (Tris HCl PH 7.5 100mM, NaCl 150 mM, 0,5% 
Blocking Reagent), and signals were visualized using the TSA Cy3 system (Perkin 
Elmer) after washing in TNT buffer (Tris HCl PH 7.5 100mM, NaCl 150 mM, 0.05% 
Tween-20) 
ISH on DIG-labeled probe was performed with monoclonal anti-DIG antibody after 
TSA reaction. To combine RNA ISH with immunofluorescence, slices were 
incubated with anti-TH antibody 1:1000 (Chemicon). Signals were then detected with 
fluorescent dye-conjugated secondary antibody goat anti-rabbit 405 and goat anti-
mouse 488. Sections were then washed, mounted with Vectashield (Vector lab) 
mounting medium and observed at confocal microscope (Leica). 
CHIP Assay 
 
Chromatin immunoprecipitation was performed with magnetic beads (Dynabeads, 
Invitrogen) following the protocol as described(Schmidt et al. 2009). For each ChIP, 
one confluent 100mm plate of MN9D-Nurr1Tet-On cells (Hermanson et al. 2003) was 
treated with doxycicline 3 µg/ml. Upon doxycicline treatment, Nurr1 expression was 
monitored by western blot. 1 µg of ChIP-grade anti-Nurr1 antibody was used (sc-990 
X). Rabbit IgG were used as negative control (Cell signalling #2729).   
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qPCR was performed with primers for DNA binding regions of indicated targets and 
distal primers were designed for an unrelated region 6000 bps upstream the AS Uchl1 
TSS: 
VMAT NBRE F: 5’-ATTGTGCTAACATTTATTCCAGAG-3’ 
VMAT NBRE R: 5’-AGGGCTTCCTACGTGACC-3’ 
OCN NBRE F: 5’-CCACAACACGCATCCTTT-3’ 
OCN NBRE R: GGACTTGTCTGTTCTGCA-3’ 
AS Uchl1 NBRE F: 5’ CTTCCCATACAGCTTAGTTCC-3’ 
AS Uchl1 NBRE R 5’-TTGCGTCTCTGCCAGATG-3’ 
Distal F 5’-TCATCCAGCCACAAGGTCAGAG-3’ 
Distal R 5’- CCAGCAGGCACACTGTTGAAC-3’ 
Enrichment of chromatin binding was calculated relative to total input, as described 
previously(Guccione et al. 2006).  
MPTP treatment  
 
Eight-week-old, male, C57BL mice (Charles River Laboratories) were subjected to a 
sub-acute MPTP regimen(Kuhn et al. 2003). Mice used in this study were treated 
according to the NIH guidelines for Care and Use of Laboratory Animals. MPTP use 
and safety precautions were as described previously(Przedborski et al. 2000). Animal 
handling and experimental procedures were performed according to guidelines of the 
University of Trieste. Animals received one intraperitoneal injection of MPTP-HCl 
(20 mg/kg free base suspended in saline; Sigma-Aldrich) or saline every 2 h for a total 
of four doses over an 8 h period. When required, animals were sacrificed. 
Post-mortem human brain samples 
 
Brain samples were obtained from the brain bank at the Institute of Neuropathology, 
Bellvitge Hospital (University of Barcelona, Spain). Samples were dissected at 
autopsy with the informed consent of patients or their relatives and the institutional 
approval of the Ethics Committee of the University of Barcelona. Brains were 
obtained from Caucasian, pathologically confirmed PD cases and age-matched 
controls. The time between death and tissue dissection was in the range of 3 to 5 
hours. Substantia nigra was excised and immediately frozen for RNA extration.  
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Western blot 
 
Cells were lysed in SDS sample buffer 2X. Proteins were separated in 15% SDS-
polyacrilamide gel and transferred to nitrocellulose membrane. Immunoblotting was 
performed with the following primary antibodies: anti-UchL1 (#3524 Cell Signalling) 
1:300, anti-Uxt (11047-1-AP Proteintech Group) and anti-β actin (A5441, Sigma) 
1:5000. Signals were revealed after incubation with recommended secondary 
antibodies conjugated with horseradish peroxidase by using enhanced 
chemioluminescence for UchL1 (#WBKLS0500 Immobilion Western 
Chemioluminescent HRP substrate) and ECL detection reagent (RPN2105, GE 
Healthcare). 
Cellular fractionation 
 
Nucleo-cytoplasmic fractionation was performed using Nucleo-Cytoplasmic 
separation kit (Norgen) according to manufacturer’s instruction. RNA was eluted and 
treated with DNAse I. The purity of the cytoplasmic fraction was confirmed by Real 
Time qRT-PCR on Pre-ribosomal RNA. 
Polysomes profiles 
 
Polysomes profiles were obtained using sucrose density gradients. MN9D cells were 
treated with 1 mg/ml rapamycin for 35 min, then with 100 mg/ml cycloheximide for 
10 min prior lysis in 150 ml lysis buffer (50mM Tris-HCl pH7.5, 100mM NaCl, 
30mM MgCl2, 100 mg/ml cycloheximide, 0.1% NP-40, 40U/ml RNasin®, protease 
inhibitors cocktail). Whole cell extracts were clarified at 4°C for 10 min at 15000g. 
The equivalent of 5-10 absorbance units at 254 nm of the clarified cell extract was 
layered onto 15%-55% (w/v) sucrose gradient (50mM Tris/acetate pH 7.5, 50 mM 
NH4Cl, 12 mM MgCl2 and 1 mM DTT) and centrifuge for 3h30 at 39000 rpm in a 
Beckman SW41Ti rotor at 4°C. The gradient was pump out by upward displacement 
and absorbance at 254mn was monitored using BioLogic LP software (Bio-Rad).  1ml 
fractions were collected, 1ml Trizol reagent (Invitrogen) was added and, RNA was 
extracted following manufacturers instructions. A fixed volume of each RNA sample 
was then retro-transcribed and percentage of mRNA in each fraction was calculated 
as relative Ct value to total RNA. 
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Bioinformatic analysis 
 
For ChIP experiments, identification of NGFI-B binding elements was performed 
with the Genomatrix program (http://genomatrix.de) and the TRANSFAC database 
(Wingender et al. 1997). The mouse AS Uchl1 genome region from kb −3000 to 
+1000 was the reference sequence. Transcriptional binding factor motifs were chosen 
on the basis of core similarity (score 1.0) and matrix similarity (above 0.80).  
For the identification of a cadidate human hortologue of AS Uchl1, conservation 
between human and mouse in the orthologus region of AS uchl1 was performed using 
VISTA genome browser. We selected parameters for conserved sequence tags (CTS) 
that have a minimum of 75% identity between the mouse and human genome. For 
each conserved element a primer on the homologus human region was designed.  
For the identification of additional translational activator candidates, we searched for 
FANTOM3 full-length cDNAs that were non-coding RNAs and overlap the 5’ end of 
coding transcripts in a head to head configuration [PMID: 16141072]. The filtered set 
of 8535 FANTOM3 ncRNA transcripts described previously(Nordstrom et al. 2009) 
was used as our starting point. Genomic locations of these ncRNA transcripts and 
REFSEQ(Maglott et al. 2000) coding transcripts were extracted from the alignments 
in the UCSC Genome browser(Kent et al. 2002) to identify a set of 788 coding-
sense/non-coding-antisense pairs. ncRNAs were then checked by RepeatMasker to 
identify SINEB2-related sequences (Smit, AFA, Hubley, R & Green, P. 
RepeatMasker Open-3.0.1996-2010 <http://www.repeatmasker.org>). This analysis 
reduced the number of pairs to 127 protein coding transcripts with overlap at the 5’ 
end (60 with a sense strand version of the repeat, 53 with an antisense version and 14 
with both sense and antisense versions).  
Alignment of the SINEB2-related elements was then carried out using Clustalw 
(http://www.ebi.ac.uk/Tools/clustalw2/index.html). From this analysis the antisense 
overlapping transcripts with a repeat most similar to the one of AS Uchl1, as well as 
in the same orientation were chosen for experimental testing (AS Uxt). 
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3. RESULTS 
 
3.1 Identification of a noncoding antisense transcript at Uchl1 locus in the 
mouse. 
 
The mouse synthenic genomic loci of 10 genes associated to familiar cases of PD 
were analyzed to identify putative noncoding antisense transcripts. By using the 
Ensembl browser (http://www.ensembl.org) ESTs and/or cDNAs were scored for 
being transcribed in the antisense direction with respect to the known gene as well as 
for its overlap at the 3’ or 5’ UTR. Furthermore, transcripts were required to be highly 
conserved across mammalian genomes. As a result, we identified Rik6430596G22 as 
a putative spliced ncRNA in the locus of the mouse Uchl1 gene that maps in antisense 
fashion to its coding counterpart. It is a typical 5’ head to head transcript that initiates 
within the second intron of Uchl1 (Figure 13). It overlaps the first 72 bps of the sense 
gene including the ATG codon. 5′ rapid amplification of cDNA ends (RACE) was 
then carried out on total RNA from MN9D cells to map the precise transcriptional 
start site (TSS) of the AS Uchl1 gene. As shown in figure 13, its TSS lies 250 bps 
upstream the previously annotated sequence and it is localized in the second intron of 
Uchl1. Two embedded repetitive sequences, SINEB2 and Alu, were revealed by 
Repeatmasker within the 3’ half of the transcript. The FANTOM2 clone spans a 
genomic region of 70kb identifying four exons whose intron-junctions follow the 
traditional GT-AG rule.  
 
 
Fig. 13  Genomic organization and expression of Uchl1 and AS Uchl1  
Genomic structure of Uchl1/AS Uchl1 locus (Chr5: 67017713-67078563) is represented in the cartoon. 
Uchl1 exons are depicted in black, transcription occurs on the genomic strand +. AS Uchl1 is 
transcribed from a TSS (Transcriptional Start Site) that lies within the second intron of Uchl1 and is 
transcribed on the strand -. The two repetive elements within the antisense are depicted in colours: alu 
in purple, SINEB2 in green. 
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3.2 AS Uchl1 is expressed in DA neurons of the SN and nuclear enriched. 
 
Multiplex RT-PCR and double in situ-hybridizations were carried out to study the 
expression pattern of the antisense gene and to compare it with its sense pair. The 
analysis of a panel of mouse adult tissues, macroscopically dissected brain regions 
and neuronal cell lines proved that AS Uchl1 expression was restricted to ventral 
midbrain and cortex in the mouse adult brain as well as in MN9D dopaminergic cells 
while it was absent in  non dopaminergic cell lines like N2A and Sdh striatal cells.  
 
Figure 14. AS Uchl1 is selectively expressed in dopaminergic cells and in Cortex. Multiplex RT-
PCR carried on 500ng of total RNA extracted from different parte of adult mouse brain (left) and 
different cell lines (right). H: Housekeeping Gapdh, AS: AS Uchl1, S: Uchl1. 
 
By taking advantage of the TH-GFP mouse line where dopaminergic (DA) cells are 
selectively labeled, Laser Capture Microdissection (LCM) technology was used to 
harvest 300 A9 DA cells from the Substantia Nigra (SN). The expression levels of 
Uchl1 and AS Uchl1 in A9 cells were then monitored by qRT-PCR and compared to 
macroscopically dissected ventral midbrain. As shown in Figure 14, while Uchl1 
mRNA was only modestly enriched when compared with total ventral midbrain (3.2 
fold), AS Uchl1 transcripts was increased in DA cells an average of 180 fold proving  
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itciscselectivelycenrichedcincthesecneuronsc(Figurec15).
 
Figure 15. AS Uchl1 is enriched in DA neurons. qPCR starting from 300 LCM-isolated  neurons 
from A9 region of the ventral midbrain of TH-GFP mice. Uchl1 and AS Uchl1 were amplified with 
intron spanning primers on three biological replica (P<0.01). 
 
In situ-hybridization was then performed on coronal sections of ventral midbrain of 
mouse adult brains with riboprobes corresponding to 600 bps of the 3’ end of Uchl1 
mRNA and to 1000 bps of the 3’ end of AS Uchl1. Both probes did not encompass 
the region of overlap. Uchl1 mRNA, as expected by comparison with the Allen Brain 
Atlas, was prevalent in the cytoplasm of cells of the hippocampus, cortex and 
subcortical regions as well as of the dorsal and ventral midbrain. In situ-hybridization 
for AS Uchl1 decorated similar structures including cortex, hippocampus and the 
midbrain (Data not shown).  
 
A combination of Double Fluorescent in situ hybridization (D-FISH) with anti-
tyrosine hydroxylase immunfuorescence was then carried out on the SN of the 
midbrain. mRNAs for Uchl1 and its AS transcript were proved to be expressed in the 
very same DA neurons of the SN (Figure 16). Intriguingly, transcripts for the 
sene/antisense pair were prevalently localized in two different subcellular 
compartments: mature Uchl1 mRNA mainly stained the cytoplasm, while the AS 
Uchl1 was nuclear, accumulating in specific subnuclear regions .  
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Figure 16. AS Uchl1 transcript is nuclear-enriched in A9 DA neurons. Ventral midbrain slices 
were processed with antisense probe for Uchl1 (digoxigenin labelled, revealed with FITC) and AS 
Uchl1 (biotin labelled, revealed with Cy3). DA neurons were visualized by immunohistochemistry 
using an anti-TH antibody (blue). The overlay (merge) shows co-localization of the transcripts of 
Uchl1 and AS Uchl1 respectively in the cytoplasm and in the nucleus of A9 neurons. The zoom offers 
magnifications of the overlay images. Scale bars indicate 10 µm. 
 
3.3 Nurr1 activity regulates AS Uchl1 expression  
 
The genomic region -3000/+1000 around its TSS was then scanned for Transcription 
Factor Binding Sites (TFBSs) known to be involved in DA-specific transcriptional 
networks. By taking advantage of MatInspector (www.genomatrix.de), TRANSFAC 
database (Kel et al. 1995) was analyzed for a core similarity of 1.0 and matrix 
similarity above 0.90. A NGFI-B element was thus identified in position -1230/-1222 
to the AS Uchl1 TSS. This TFBS is the target of the Nurr subfamily of nuclear 
receptors including Nurr-1, a key dopaminergic transcription factor required for late-
dopaminergic differentiation and crucial for the expression of several dopaminergic-
specific genes like VMAT2, AADC, DAT and TH (Castro et al. 2001). Nurr-1 binds 
DNA in an orientation-dependent manner on the NBRE site AAAGGTCA (Wilson et 
al. 1991) with a possible variation around the core motive responding to 
RxR/Retinoids Nurr subfamily of nuclear receptors AGGTCA. To validate the Nurr-1 
dependency of AS Uchl1 expression, we took advantage of a stable MN9D cell line 
overexpressing Nurr-1 under a doxycicline inducible promoter MN9D-Nurr1Tet-On 
(Hermanson et al. 2003). Upon drug treatment, AS Uchl1 underwent a rapid 
upregulation starting from 12 hours, with kinetics comparable to the one observed for 
VMAT2, a well-known primary target of Nurr-1. Within 48 hours, both AS Uchl1 
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andcVMAT2cmRNAscreachedctheircpeakcofcinductionc(Figurec17a). 
  
Figure 17. AS Uchl1 is primary target of a dopaminergic specific TF Nurr-1 a, Quantification of 
Uchl1, AS Uchl1 and VMAT2 RNA expression during in-vitro dopaminergic differentiation of MN9D 
cells stabily expressing Nurr-1 under doxycicline-inducible promoter (on the left). Cells are harvested 
at the following time points after drug exposure: 16, 24, 48, 96 hrs * P<0.05, ** P<0.01. b, Chromatin 
immunoprecipitation of the NGFI-B response element (NBRE) present on VMAT2, OCN and AS 
Uchl1 promoters (on the right), % of the bound DNA is shown on the Y axes, evaluated as Dct of Nurr-
1 (Ct Nurr-1 IP-Ct Imput) compared with Dct IgG control (Ct IgG IP-Ct Imput). 
 
The physical binding of Nurr-1 to the NGFI-B element was then proved by chromatin 
immunoprecipitation (ChIP) of Mn9D cells after 12 hours of doxycicline induction, 
when Nurr-1 protein concentration is the highest. Chromatin-protein complexes were 
immunoprecipitated with anti-Nurr-1 or control (IgG) antibodies and bound genomic 
DNA was quantified by qPCR using primers for Nurr-1 response elements in AS 
Uchl1, Osteocalcin and Vescicular Monoamine Transporter 2 gene promoters. PCR 
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reactions generated only the expected specific amplicon, as detected by gel 
electrophoresis and melting curve analysis (data not shown). As in Figure 17b, Nurr-
1 binding was significantly enriched relative to IgG control. 
These data strongly suggest that AS Uchl1 is a primary target of Nurr-1 activity and a 
component of its dopaminergic-specific gene network. On the contrary, its sense, 
protein encoding counterpart is not since no Nurr-1 binding site was found in the 
Uchl1 promoter and the kinetics and strength of Uchl1 mRNA upregulation was 
different from VMAT2. 
3.4. AS Uchl1 and Uchl1 are downregulated in neurochemical models of PD. 
 
Since Uchl1 protein is downregulated and inactivated in sporadic PD post-mortem 
brains, the behaviour of the sense/antisense pair was investigated in neurochemical 
modelscofcthecdisease. 
 
Figure 18. Uchl1/AS Uchl1 SAP are downregulated by PD-like stimuli in-vitro and in-vivo mouse 
models and in post-mortem SN of PD patients. a, qRT-PCR of Uchl1 and AS Uchl1 transcript levels 
in MN9D cells treated overnight with 100 uM of MPP+ (on the left). b, qRT-PCR of Uchl1 and AS 
Uchl1 transcripts  perfomed on 300 A9 dopaminergic cells harvested with LCM from mice treated with 
MPTP (2 days and 7 days after last MPTP injection). Control mice are injected with saline control 
solution. n=3 mice per time point. * P<0.05, ** P<0.01, *** P<0.001. 
 
 
When MN9D neuronal cells were exposed to 100 uM MPP+ for 16 hours, Uchl1 
mRNA was reduced to 0.72 of its physiological level, while the antisense transcript 
was reduced to 0.27 (Figure 18a). Sub-chronic administration of MPTP was then 
carried out on 8 months old TH-GFP mice and 300 A9 neurons were purified by LCM 
in three biological replicates. While modest but significant (P>0.05) downregulation 
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of Uchl1 was observed (0.67 at day 7 compared to the control), expression of AS 
Uchl1 was almost completely abolished after 7 days (Figure 18b). 
 
3.5 Cloning of human AS UCHL1 and analysis of its expression in post-mortem 
brains of PD patients. 
 
A 70-kb region of the mouse genome encompassing the AS UchL1 locus was 
compared to the corresponding human genomic sequence using Genome Vista 
alignmentc(http://genome.lbl.gov/cgi-bin/GenomeVista). 
 
Figure 19. hAS UCH-L1/UCH-L1 are downregulated in in post-mortem SN of PD patients. a, 
Cartoon representing the structure of the human S/AS pair locus (chr4: 41,222,681-41,258,935) 
including the partial AS UCHL1 human clone, amplified from human total brain RNA. b, Total RNA 
was extracted from SN of five PD and three control brains. hUCHL1 and  hAS UCHL1 levels were 
measured by qPCR. Open (PD cases) and full (controls) squares represent single expression values, 
dashes between the squares represent the average expression. Significance between PD and control 
group was calculated with t-test.  
 
 
By the use of primers designed on the human sequence in correspondence to the 
regions of highest conservation (Conserved Sequence Tags peaks), a 1.2 kb 
noncoding transcript, 5’ head to head antisense to human UCHL1 gene, was cloned 
from human brain RNA. The anatomical organization of hAS UCHL1 gene was very 
similar to its mouse counterpart including the extension of the sense/antisense pair 
overlap region as well as the presence of embedded repetitive elements (Alu element 
in blue, (Figure 19a). As its murine counterpart, hAS UCHL1 expression was highly 
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restricted to human brain (data not shown). Since UCHL1 espression was reported to 
be downregulated in PD patients, 5 SN post-mortem samples with a clinical diagnosis 
of PD versus 3 age-matched healthy controls were used in RT-PCR to evaluate hAS 
UCHL1 mRNA levels. Both UCHL1 and its AS UCHL1 underwent a significative 
downregulation in all the patients, which is an average of 0.47 of the control level for 
AS UCHL1 and 0.36 for UCHL1 (Figure 19b).  
3.5 AS Uchl1 causes Uchl1 protein upregulation in an embedded SINEB2-
dependent fashion. 
 
The full length cDNA of AS Uchl1 was then cloned from Mn9D cells and used in the 
subsequent functional analysis. The interplay between the sense and the antisense 
transcript was then examined by transiently overexpressing AS Uchl1 in MN9D 
dopaminergic cells and monitoring endogenous Uchl1 mRNA and protein levels by 
qRT-PCR and western blotting.  
 
Figure 20. AS Uchl1 regulates Uchl1 translation. AS Uchl1-transfected dopaminergic MN9D cells 
show increased levels of endogenous Uchl1 protein relative to empty vector control, with unchanged 
mRNA quantity. b, Increasing doses of transfected AS Uchl1 titrate quantity of translated Uchl1 
protein in HEK 293T cells. No changes in Uchl1 mRNA levels. 
 
While no significant change in Uchl1 mRNA endogenous levels was observed if 
compared with empty vector-transfected cells, a strong and reproducible upregulation 
of UchL1 protein product was detected within 24 hours (Figure 20a). We thus 
resorted to Hek T cells that do not express both transcripts to assess whether the 
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cotransfection of both cDNAs was able to recapitulate what observed on the 
endogenous Uchl1 transcript in MN9D cells. When increasing amounts of AS Uchl1 
was co-transfected with murine Uchl1, a dose-dependent UchL1 protein upregulation 
was observed (Figure 20b) in absence of any significant change in exogenous Uchl1 
mRNA level.  
 
 
Figure 21. AS Uchl1 regulates Uchl1 translation via embedded SINEB2. a, Full length (FL) AS 
Uchl1 is required for regulating endogenous (MN9D cells, left panel) and overexpressed (HEK 293T 
cells, right panel) Uchl1 protein levels. Scheme of D5’ or D3’ deletion mutants is shown. b, Inverted 
SINEB2 is sufficient to control Uchl1 protein levels. Scheme of mutants is shown.  
 
To identify sequences and/or structural elements of AS Uchl1 mRNA that elicit its 
functional activity on UchL1 protein, deletion mutants were produced and tested  in 
MN9D cells as well as in co-transfection in Hek cells. AS Uchl1 Δ5’ lacked the 5’ 
sequence overlapping Uchl1 first exon while AS Uchl1 Δ3’ did not contained the last 
three exons of the antisense gene. Neither the Δ3’ nor the Δ5’ transcripts were able to 
upregulate endogenous UchL1 protein levels in dopaminergic MN9D (Figure 21a) 
and in cotransfection in Hek cells (Figure 21a). Titration of the endogenous level of 
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Uchl1 in transfected MN9D cells was evaluated with qPCR, and no significant change 
in its mRNA expression was noticed. Additional deletion mutants were then 
synthesized to assess the role of the embedded repetitive sequences in UchL1 protein 
upregulation: the ΔSINEB2+Alu (ΔAS), the ΔSINE B2 (ΔS) (764-934) and the ΔAlu 
ΔA (1000-1045). While the ΔAlu mutant showed a comparable effect on UchL1 
protein upregulation as full length AS Uchl1, the ΔSINEB2+Alu and the ΔSINEB2 
mutants were unable to do so proving a functional role of the embedded SINEB2 
(Figure 21b).  No change in Uchl1 mRNA level was observed. Since the deletion 
mutant ΔSINEB2 lacks 170 nucleotides potentially impairing AS Uchl1 RNA 
secondary structure, a mutant was produced with the SINEB2 sequence flipped in 
between nucleotide 764-934. Interestingly, SINEB2 flip was unable to increase 
UchL1 protein levels in transient transfection thus proving the orientation-dependent 
activity of the SINEB2 domain (Figure 21b, right). 
3.6 Rapamycin induces shuffle of AS Uchl1 mRNA into the cytoplasm.  
 
Several stressors that have been implicated in PD pathogenesis were then assayed for 
their ability to shuffle the nucleus-retained AS Uchl1 mRNA into the cytoplasm. 
Figure 22. Rapamycin induces AS Uchl1 accumulation in the cytoplasm. qPCR for AS Uchl1 carried 
on cytoplasmic RNA samples of MN9D cells exposed to hydrogen peroxide 1mM, serum starvation, 
rapamycin 1 ug/ml, tunycamycin 20nM and TNFalpha 20 nM for 45 minutes. Differential 
contamination of nuclear RNA was evaluated with pre-ribosomal RNA titration in each sample. 
 
 
MN9D cells were exposed to hydrogen peroxide 1mM, serum starvation, rapamycin 1 
ug/ml, tunycamycin 20nM and TNFalpha 20 nM for 45 minutes and AS Uchl1 
mRNA content was independently measured in the cytoplasm and nucleus by qRT-
PCR. While for the majorities of treatments no effect was detected, a strong 
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upregulation of 4-5 fold for AS Uchl1 cytoplasmic mRNA occurred upon exposure to 
Rapamycin (Figure 22).  
 
Figure 23. AS Uchl1-embedded SINEB2 induces translation of Uchl1 upon rapamycin treatment. 
a, Uchl1 protein level is increased in rapamycin-treated MN9D cells. b, AS Uchl1 translocates to the 
cytoplasm upon rapamycin treatment in MN9D cells. mRNA levels measured with primers spanning 5’ 
overlapping or 3’ distal portions of the transcript. Data indicate mean ± s.d., n≥3 (3). **p<0.01; 
***p<0.005. 
 
 
Rapamycin is a well-known inhibitor of cellular translation through its activity on 
mTOR and it is currently included in clinical trials for neurodegenerative diseases. 
The effects of rapamycin were thus studied in more details confirming the 
redistribution of AS Uchl1 from the nucleus to the cytoplasm in the absence of 
changes in total cellular content of the transcript (Figure 23b, right). A concomitant 
analysis of Uchl1 mRNA showed no changes in subcellular distribution, de novo 
transcription and total cellular content (Figure 23b, left). However, in the very same 
samples UchL1 protein level increased several fold upon rapamycin treatment (Figure 
23a). 
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3.7 AS Uchl1 mediates rapamycin-induced UchL1 protein upregulation. 
 
Since the effects of rapamycin on UCH-L1 protein levels were concomitant to AS 
Uchl1 mRNA redistribution from the nucleus to the cytoplasm, we assessed whether 
AS Uchl1 was required for UchL1 induction by interfering with AS Uchl1 mRNA 
expression and function. Small 21-25 nucleotides RNAs directed to gene promoters 
have been reported to silence gene transcription in a methylation-dependent manner 
or causing steric interference to the transcriptional apparatus by triple helix formation 
(Morris et al. 2004). 
 
 
Figure 24. a, Silencing AS Uchl1 transcription in MN9D cells (shRNA, encompassing -15/+4 position 
of target sequence) doesn not affect mRNA levels. Scramble, shRNA control sequence b, In silenced 
cells rapamycin-induced Uchl1 protein translation is inhibited.  
 
Stable MN9D cell lines were then established expressing constitutively shRNA for 
AS Uchl1. This sequence targeted AS Uchl1 promoter region from -4 to + 15 nt 
around the RACE-validated TSS. A single clone showing more than 50% silencing 
with respect to the scrambled control was chosen for the analysis of the effects of 
rapamycin treatment (1ug/ml). While scrambled cells showed UchL1 protein 
upregulation as in MN9D parental line, cells expressing the shRNA for AS Uchl1 
presented a strong downregulation of UchL1 protein proving a causal link between 
rapamycin induction of Uchl1 protein and AS Uchl1 mRNA expression (Figure 24). 
 
 64 
 
Figure 25. Deletion of embedded SINEB2 (DSINEB2) inhibits rapamycin-induced Uchl1 protein 
up-regulation. As in Figure 24 a, overexpression of AS uchl1 ΔSINEB2 does not affect Uchl1 mRNA 
levels. pcDNA 3.1 control clone b, In ΔSINEB2 cells  rapamycin-induced Uchl1 protein translation is 
inhibited.  
 
As an indipendent model, we established stable cell lines constitutively expressing AS 
Uchl1 ΔSINEB2 and empty vector as control to take advantage of the dominant 
negative properties of this construct on the activity of full length AS Uchl1. As 
expected, when polyclonal stable MN9D cells for empty vector pcDNA 3.1 were 
treated with rapamycin, UchL1 protein was found increased. In presence of the 
dominant negative form of AS Uchl1 ΔSINEB2, this upregulation was no longer 
visible (Figure 25, right). 
3.8 Analysis of association of polysomes upon rapamycin treatment. 
 
Association of Uchl1 mRNA to polisomes was then monitored upon rapamycin 
treatment to assess the role of translation in UchL1 protein induction. MN9D cells 
were treated with Rapamycin 1ug/ml for 45 minutes and with vehicle DMSO as 
control. Cytoplasmic extracts were prepared and fractionated through sucrose 
gradients. Thirteen fractions were collected from each gradient while recording the 
absorbance profile. Distribution of specific transcripts was assayed with qRT-PCR. 
Uchl1 mRNA was found increased in fraction 12 of 1.54 fold upon rapamycin 
treatment, showing an enhanced polysome association (Figure 26a). mRNAs of  β-
actin show a pattern similar for DMSO and Rapamycin treated cells since no variation 
of polysomal association can be observed in the different growth conditions (Figure 
26b). Rack1 transcript distribution was also studied as representative of TOP mRNAs 
which translation is specifically suppressed by rapamycin (Jefferies et al. 1997). As 
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expected, Rack-1 mRNA was mostly associated with polysomes in growing cells 
(DMSO), but shifted to subpolysomal particles after rapamycin treatment 
(Figure26c). 
 
 
Figure 26. Uchl1 associated with polysomal fraction upon rapamycin treatment. qRT-PCR for a, 
Uchl1 b, β-actin and c, Rack-1 was performed on RNA extracted from 14 sucrose gradient fractions of 
MN9D cells (Ctr) and stable AS Uchl1 DSINEB2 mutant (DSINEB2) treated with rapamycin or 
vehicle alone (DMSO), as indicated. Association with each fraction is shown as percentage of total 
mRNA.  
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3.9 AS Uchl1 identifies a new functional class of noncoding antisense RNA. 
 
The collection of FANTOM3 non-coding cDNAs was bioinformatically screened for 
clones representing natural antisense transcript 5’ head to head overlapping to protein 
coding genes. This list was subsequently analyzed for the presence of embedded 
SINEB2 of the B3 type in reverse complement orientation in the 3’ half of mRNA. 31 
transcripts and SAP were thus identified (Figure 27a). On the bases of the expression 
of their protein coding mRNA counterpart in MN9D dopaminergic cells (Biagioli et 
al. 2009), an antisense RNA Rik4833404H03 to the Ubiquitously expressed transcript 
Uxt  (NM_013840) was then chosen (Figure 27b) and tested for its ability to induce 
upregulation of the sense protein coding overlapping gene. Transfection of AS Uxt in 
MN9D dopaminergic cell shows transient upregulation of Uxt protein product with no 
change in the total mRNA levels. (Figure 27c). 
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Figure 27. Family of AS transcripts with embedded SINEB2. a, Family of FANTOM 3 non-coding 
clones that are AS to protein coding genes and contain embedded SINEB2 in inverted orientation. b, 
Schematic diagram of Uxt/AS Uxt genomic organization. c, AS Uxt increases endogenous Uxt protein 
levels in transfected MN9D cells (left), without affecting its transcription (right).  
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4 DISCUSSION 
 
Recently several long non-coding RNAs (lncRNAs) have been found in the mouse 
genome (Carninci et al. 2006). This set of transcripts displays a clear evolutionary 
conservation, thus suggesting a potential biological role. Correlation studies show that 
nuclear lncRNAs are involved in several biological processes from stem cell 
pluripotency to cell cycle regulation (Chen and Carmichael 2010; Guttman et al. 
2009; Huarte et al. 2010). Numerous lncRNAs are physically associated with 
chromatin-modifying complexes at the promoter of repressed genes (Huarte et al. 
2010) or they can either function as enhancer elements permitting the transcription of 
neighbouring protein coding genes (Feng et al. 2006). In the widest class of long non- 
coding RNAs, antisense RNAs represent a powerful subclass of ncRNAs for one main 
reason: antisense RNAs contain both the information necessary for target recognition 
(the overlapping sequence with protein coding transcript) and additional analogical or 
digital features for interaction with RNA binding proteins and/or co-factors. Antisense 
RNAs can then be the perfect candidate for post-transcriptional regulation of gene 
expression.  
Here we report a novel function for a nuclear lncRNAs AS Uchl1 in the post-
transcriptional control of gene expression of its sense mRNA Uchl1.  
4.1 AS Uchl1 is expressed in dopamnergic cells of the substantia nigra. 
 
By taking advantage of two indipendent approaches: LCM and Fluorescent in-situ 
hybridization, we detected the expression of AS Uchl1 in the A9 neurons of the 
Substantia Nigra. Interestingly, while Uchl1 is widespreadly expressed in mammalian 
brain, AS Uchl1 is found to be selectivly expressed in two sites of the brain, the 
Cortex and the Substantia Nigra. Spacial or temporal restricted expression pattern for 
ncRNAs is a very important element to address its functional role.  
We revealed that AS Uchl1 is target of specific dopaminergic network responding to 
Nurr-1 activation, by using an in-vitro model of dopaminergic differentiation MN9D 
dopaminergic cells MN9D-Nurr1Tet-On cells. 
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4.2 AS Uchl1 is stress-responding lncRNA. 
 
From transient transfection experiments it emerged that AS Uchl1 was able to drive 
Uchl1 protein upregulation and that this activity was dependent on the presence of a 
SINEB2 repetitive element. 
As shown by Fluorescent in-situ hybridization and nucleo-cytoplasmic franctionation, 
the Uchl1 antisense was enriched in the nucleus. Rapamycin treatment is able to 
mobilize endogenous AS Uchl1 from nucleus to the cytoplasm, where concomitant 
increase of Uchl1 mRNA association to polysomes takes place.  
Taking advantage of two cell lines, the siRNA AS Uchl1 and the AS Uchl1 ΔSINEB2 
we determined the functional role of AS Uchl1 in rapamicin-induced UchL1 protein 
upregulation. 
Rapamycin impairs cap-dependent translation, by blocking mTORC1 kinase, which 
normally activates the eIF4F complex (Andrei et al. 2005; Holcik and Sonenberg 
2005). A similar regulatory system occurs upon stress, when regular cap-dependent 
translation of most proteins is greatly reduced (Patel et al. 2002) and the expression of 
a small group of proteins such as heat shock proteins or genes involved in survival or 
apoptosis is greatly enhanced (Lu et al. 2006; Rhoads and Lamphear 1995). The 
mechanisms that account for the selective translation of certain mRNAs, while overall 
translation is momentaneously halted, are still incompletely understood but they may 
include internal ribosome entry sites and ribosome shunting (Gilbert 2010; Rubtsova 
et al. 2003). They do not require IF4F. Indeed, IRES-mediated translation is 
prominent in conditions of stress or growth factor inhibition and its alteration affects 
processes such as tumorigenesis (Holcik and Sonenberg 2005; Yoon et al. 2006). 
These findings are consistent with the idea that acute stress response does not increase 
production of new transcripts, but affects the post-transcriptional regulation of 
previously synthesized mRNAs that are in the cytoplasmic cohort. 
In mice rapamycin shows both in-vitro and in-vivo protection for DA neurons upon 
neurochemical intoxication and alleviates L-DOPA induced diskynesia in humans 
(Malagelada et al. 2010; Santini et al. 2009). The protective effect exerted by 
rapamycin on neurons has been explained by both induction of autophagy (Sarkar et 
al. 2009) and suppression of RTP801 translation (Malagelada et al. 2006b). We know 
that after rapamycin treatment AS Uchl1 re-localize into the cytoplasm and rescues 
Uchl1 from occurring block of translation. 
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Interestingly, UchL1 is a pro-survival protein for neurons, reason why the 
manipulation of its expression has been proposed for intervention in 
neurodegenerative diseases, including PD and AD.  
We propose that the antisense-driven elevation of UchL1 in dopaminergic cells that 
occurs upon rapamycin might be an additional molecular event to explain the 
protective effect previously recognized for this drug in neurons.  
4.3 New class of lncRNAs 
 
The mechanism proposed for AS Uchl1 suggest the intriguing idea that it might exist 
a pool of cellular nuclear-retained RNAs, normally kept latent in the nucleus that are 
ready to respond to acute stimuli by changing their subcellular location. We already 
know that stress-dependent nuclear-cytoplasm shuttling of lncRNAs seems to be a 
common strategy to regulate translation since CTN-RNA, another nuclear-retained 
lncRNA, unveiled a cryptic protein coding sequence at its 3’end when in the 
cytoplasm (Prasanth et al. 2005). By changing location, RNA molecules can be able 
to exert their specific function, i.e. for AS Uchl1 using the SINEB2 module to 
increase protein translation and the 5’ overlaps to target the sense mRNA. 
We thus clustered several antisense transcripts that are overlapping 5’ head to head to 
RefSeq genes in mouse and have a SINEB2 element in reverse complement within 
their sequence. From this list we experimentally found that a second antisense RNA 
(AS Uxt) is able to drive protein upregulation of its protein-coding overlapping 
partner. These results suggests that AS Uchl1 and AS Uxt may be a representative 
member of a new functional class of lncRNAs that are associated to S/AS pairs in the 
mammalian genome . They require an overlap at the 5’ end and the action of a 
SINEB2 repeat. The region at the 5’ provides specificity to a protein-encoding mRNA 
partner transcribed from the complementary strand. An inverted SINEB2 element at 
the 3’ is required for translational activation.  
It will be interesting in the future to capture all the transcripts that contain a reverse 
complement SINEB2 element via Deep Sequencing of 5’RACE products obtained 
from SINEB2 internal primer, thus profiling all the cellular pool of non-coding RNAs 
that can use this SINEB2 module to enhance translation. 
It is also reasonable that all the ncRNA molecules capable to reprogram translation of 
cognate protein-coding mRNAs via a SINEB2 module may represent a new potential 
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pharmacological target for pathologies where these proteins are down-regulated 
and/or inactivated. 
4.4 LncRNAs as fine-tuners of gene expression in the brain 
  
Besides the role that ncRNAs have in several biological systems, they have emerged 
as particularly relevant players in a sophisticated place like the CNS, where the major 
diversity of ncRNAs is found (in particular lncRNAs (Mercer et al. 2008).  
LncRNAs generally play a role by modulating the transcription, post-transcriptional 
processing, and translation of mRNAs. In the central nervous system they play 
additional roles in mediating nervous system development, homeostasis, stress 
responses and plasticity (Qureshi et al. 2010). Moreover, lncRNAs are involved in the 
pathophysiology of a spectrum of CNS pathologies including neurodevelopmental, 
neurodegenerative, neuro-oncological and psychiatric diseases. 
LncRNAs are implicated in the pathophysiology of neurodevelopmental disorders 
associated with genomic imprinting, such as Prader–Willi syndrome (PWS) and 
Angelman syndrome (AS) (Koerner et al. 2009). 
As an example of neurodegenerative disorder, deregulation of lncRNAs has been 
assessed for AD, where the levels of lncRNA AS BACE1 are correlated with higher 
BACE1 protein which, in turn, leads to increased production of Aβ peptide (Faghihi 
et al. 2008). Another study utilized human AD brain tissue to link alterations in levels 
of  lncRNA BC200 with AD pathogenesis. Increased levels of BC200 were found in 
brain regions that are preferentially affected in AD (Mus et al. 2007). 
Pathways related to lncRNA are altered in CNS tumors, where a subset of lncRNAs 
are associated to p53 cis-regulatory elements on the promoter of genes that are 
specifically induced in response to DNA damage (Guttman et al. 2009). These 
lncRNAs have probably a fundamental role in the p53-mediated induction of cell 
cycle arrest, DNA repair and apoptosis that protect neural cells from DNA damage 
and transformation (Tedeschi and Di Giovanni 2009). 
Moreover lncRNAs are known targets of the master epigenetic regulator REST/NRSF 
(repressor element-1 silencing transcription factor/neuron-restrictive silencing factor) 
in both mouse and human (Johnson et al. 2009). Deregulation of REST and CoREST 
functions is linked to a range of CNS pathologies that include cancer (glioblastoma, 
medulloblastoma, and neuroblastoma), neurodegenerative disease (Huntington's 
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disease), neurodevelopmental disorder (Down syndromeand X-linked mental 
retardation), epilepsy, and Ischemia (Qureshi and Mehler 2009).  
Neurological disorders like epileptogenesis involve BC1/BC200 brain-specific 
lncRNAs and Evf2, since they modulate neural network plasticity and excitability 
(Mercer et al. 2008; Qureshi et al. 2010). 
In addition to neurological diseases, a number of psychiatric disorders have also been 
associated with lncRNAs. For example, the disruption of the DISC sense/antisense 
genomic locus, which encodes both the DISC1 protein-coding gene and the DISC2 
lncRNA, has been linked to the risk of developing schizophrenia, schizoaffective 
disorder, bipolar disorder, major depression, and autistic spectrum disorders (Chubb 
et al. 2008; Williams et al. 2009). 
Previous genetic linkage studies on brain diseases have revealed that a significant 
percentage of loci map to non-protein-coding regions of the genome. If we now 
consider the abundance of antisense and other lncRNAs in the brain it will be 
interesting to define if those previously identified disease association signals are 
linked to lncRNAs. 
This might be relevant for understanding in depth the genetic program of a complex 
system like the brain in its development as well as in its ability to learn and to adapt.  
Moreover the discovery of new non-coding molecules in the brain can constitute a 
starting point for the development of novel diagnostic and/or therapeutical approaches 
directed for example, to those lncRNAs whose down-regulation (or over-expression) 
is aberrant in CNS disorders.  
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